{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 207,
   "metadata": {},
   "outputs": [],
   "source": [
    "def sales(state):\n",
    "    import csv\n",
    "\n",
    "    temp = {}\n",
    "\n",
    "    # opening the CSV file\n",
    "    with open('usa.csv', mode='r') as file:\n",
    "        # reading the CSV file\n",
    "        csvFile = csv.DictReader(file)\n",
    "\n",
    "        # displaying the contents of the CSV file\n",
    "        for lines in csvFile:\n",
    "            if (lines['Prscrbr_Geo_Desc'] == state):\n",
    "                words = lines['Gnrc_Name']\n",
    "                count = int(lines['Tot_Clms'])\n",
    "                words = words.split('/')\n",
    "                for word in words:\n",
    "                    word = word.lower()\n",
    "                    if word in temp:\n",
    "                        temp[word] += count\n",
    "                    else:\n",
    "                        temp[word] = count\n",
    "                        \n",
    "    return temp\n",
    "\n",
    "#print(dict)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Alabama', 'Alaska', 'American Samoa', 'Arizona', 'Arkansas', 'Armed Forces Central/South America', 'Armed Forces Europe', 'Armed Forces Pacific', 'California', 'Colorado', 'Connecticut', 'Delaware', 'District of Columbia', 'Florida', 'Foreign Country', 'Georgia', 'Guam', 'Hawaii', 'Idaho', 'Illinois', 'Indiana', 'Iowa', 'Kansas', 'Kentucky', 'Louisiana', 'Maine', 'Maryland', 'Massachusetts', 'Michigan', 'Minnesota', 'Mississippi', 'Missouri', 'Montana', 'National', 'Nebraska', 'Nevada', 'New Hampshire', 'New Jersey', 'New Mexico', 'New York', 'North Carolina', 'North Dakota', 'Northern Mariana Islands', 'Ohio', 'Oklahoma', 'Oregon', 'Pennsylvania', 'Puerto Rico', 'Rhode Island', 'South Carolina', 'South Dakota', 'Tennessee', 'Texas', 'Unknown', 'Utah', 'Vermont', 'Virgin Islands', 'Virginia', 'Washington', 'West Virginia', 'Wisconsin', 'Wyoming']\n",
      "{'0.9 % sodium chloride': 7625, 'aa 4.25%': 11, 'calcium': 11, 'lytes': 11, 'dex 10%': 11, 'aa 5%': 25, 'd15w': 25, 'electrolytes': 25, 'abacavir sulfate': 1192, 'lamivudine': 2159, 'abacavir': 2838, 'dolutegravir': 3905, 'lamivudi': 2819, 'zidovudine': 575, 'abaloparatide': 827, 'abatacept': 1397, 'maltose': 129, 'abemaciclib': 352, 'abiraterone acet,submicronized': 86, 'abiraterone acetate': 2093, 'acalabrutinib': 468, 'acamprosate calcium': 416, 'acarbose': 3114, 'acebutolol hcl': 2893, 'acetaminophen with codeine': 46742, 'acetaminophen': 1142823, 'caff': 987, 'dihydrocod': 337, 'acetazolamide': 3892, 'acetic acid': 757, 'acetohydroxamic acid': 13, 'acetylcysteine': 372, 'acitretin': 708, 'aclidinium bromide': 163, 'acyclovir': 26288, 'adalimumab': 11097, 'adapalene': 78, 'benzoyl peroxide': 74, 'adefovir dipivoxil': 22, 'afatinib dimaleate': 75, 'agalsidase beta': 26, 'albendazole': 112, 'albuterol sulfate': 298146, 'alcaftadine': 65, 'alclometasone dipropionate': 1253, 'alcohol antiseptic pads': 13800, 'alectinib hcl': 80, 'alendronate sodium': 78872, 'vitamin d3': 18, 'alfuzosin hcl': 10946, 'alirocumab': 4134, 'aliskiren hemifumarate': 883, 'aliskiren': 278, 'hydrochlorothiazide': 678395, 'allopurinol': 168060, 'almotriptan malate': 71, 'alogliptin benz': 106, 'metformin hcl': 574831, 'pioglitazone': 76, 'alogliptin benzoate': 531, 'alosetron hcl': 252, 'alpelisib': 121, 'alpha-1-proteinase inhibitor': 1192, 'alprazolam': 272606, 'amantadine hcl': 7670, 'ambrisentan': 1916, 'amifampridine phosphate': 13, 'amikacin liposomal': 149, 'neb.accessr': 149, 'amikacin sulfate': 422, 'amiloride hcl': 1153, 'amiloride': 909, 'aminocaproic acid': 35, 'amiodarone hcl': 60339, 'amitriptyline hcl': 91195, 'amitriptyline': 200, 'chlordiazepoxide': 921, 'amlodipine benzoate': 21, 'amlodipine bes': 2710, 'olmesartan med': 2710, 'amlodipine besylate': 844135, 'benazepril': 59562, 'valsartan': 107179, 'amlodipine': 3788, 'atorvastatin': 1845, 'hcthiazid': 3868, 'ammonium lactate': 4734, 'amoxapine': 77, 'amoxicillin': 214121, 'potassium clav': 84563, 'amphetamine': 58076, 'amphetamine sulfate': 40, 'ampicillin sodium': 342, 'sulbactam na': 153, 'ampicillin trihydrate': 2339, 'anagrelide hcl': 573, 'anakinra': 100, 'anastrozole': 17729, 'apalutamide': 902, 'apixaban': 286323, 'apomorphine hcl': 73, 'apraclonidine hcl': 56, 'apremilast': 2111, 'aprepitant': 18, 'arformoterol tartrate': 112, 'aripiprazole': 58034, 'aripiprazole lauroxil': 1708, 'aripiprazole lauroxil,submicr.': 24, 'armodafinil': 3501, 'asenapine maleate': 2681, 'asfotase alfa': 13, 'aspirin': 5356, 'dipyridamole': 4895, 'atazanavir sulfate': 385, 'cobicistat': 1924, 'atenolol': 131505, 'chlorthalidone': 63938, 'atezolizumab': 18, 'atomoxetine hcl': 2663, 'atorvastatin calcium': 837843, 'atovaquone': 417, 'proguanil hcl': 103, 'atropine sulfate': 2184, 'avatrombopag maleate': 41, 'axitinib': 245, 'azathioprine': 8109, 'azelaic acid': 719, 'azelastine hcl': 39918, 'azelastine': 931, 'fluticasone': 114801, 'azilsartan med': 1310, 'azilsartan medoxomil': 1114, 'azithromycin': 160369, 'aztreonam': 125, 'aztreonam lysine': 46, 'bacitracin': 1259, 'polymyxin b sulfate': 535, 'baclofen': 95492, 'baloxavir marboxil': 1184, 'balsalazide disodium': 2104, 'baricitinib': 163, 'bcg live': 11, 'becaplermin': 100, 'beclomethasone dipropionate': 1569, 'belatacept': 13, 'belimumab': 1240, 'bempedoic acid': 131, 'ezetimibe': 93753, 'benazepril hcl': 49129, 'bendamustine hcl': 18, 'benralizumab': 170, 'benzonatate': 116, 'benztropine mesylate': 42425, 'bepotastine besilate': 437, 'besifloxacin hcl': 1219, 'betamethasone dipropionate': 10527, 'betamethasone valerate': 3144, 'betamethasone': 4689, 'propylene glyc': 4445, 'betaxolol hcl': 492, 'bethanechol chloride': 5023, 'bevacizumab': 53, 'bexarotene': 139, 'bicalutamide': 5424, 'bictegrav': 5960, 'emtricit': 6825, 'tenofov ala': 5960, 'bimatoprost': 27162, 'binimetinib': 57, 'bismuth': 59, 'metronid': 59, 'tetracycline': 59, 'bisoprolol fumarate': 28450, 'bisoprolol': 26117, 'bortezomib': 18, 'bosentan': 466, 'bosutinib': 201, 'brexpiprazole': 5462, 'brimonidine tartrate': 56265, 'timolol': 24623, 'brinzolamide': 10020, 'brimonidine tart': 6615, 'brivaracetam': 1133, 'brodalumab': 59, 'bromfenac sodium': 4933, 'bromocriptine mesylate': 995, 'budesonide': 74219, 'formoterol fumarate': 65251, 'glycopyr': 152, 'formoterol': 8172, 'bumetanide': 39889, 'buprenorphine': 7931, 'buprenorphine hcl': 51670, 'naloxone hcl': 48978, 'bupropion hbr': 88, 'bupropion hcl': 123915, 'buspirone hcl': 132946, 'butalb': 15588, 'caffeine': 16715, 'butalbit': 650, 'acetamin': 650, 'codeine': 1165, 'butalbital': 2084, 'butorphanol tartrate': 1348, 'c1 esterase inhibitor': 50, 'c1 esterase inhibitor, recomb': 56, 'cabergoline': 1118, 'cabozantinib s-malate': 282, 'calcifediol': 1240, 'calcipotriene': 1817, 'calcitonin,salmon,synthetic': 2801, 'calcitriol': 14247, 'calcium acetate': 6809, 'canagliflozin': 18528, 'candesartan cilexetil': 4921, 'candesartan': 1546, 'hydrochlorothiazid': 97639, 'cannabidiol (cbd)': 593, 'capecitabine': 16, 'capmatinib hydrochloride': 12, 'captopril': 2310, 'carbamazepine': 26368, 'carbidopa': 55610, 'levodopa': 55430, 'entacapone': 4385, 'carbinoxamine maleate': 153, 'carboplatin': 71, 'cariprazine hcl': 7020, 'carisoprodol': 4873, 'carteolol hcl': 257, 'carvedilol': 371444, 'carvedilol phosphate': 1385, 'cefaclor': 156, 'cefadroxil': 1650, 'cefazolin sodium': 1279, 'cefdinir': 60946, 'cefepime hcl': 2301, 'cefepime hcl in dextrose 5 %': 44, 'cefixime': 92, 'cefoxitin sodium': 48, 'cefpodoxime proxetil': 1453, 'cefprozil': 1412, 'ceftaroline fosamil acetate': 124, 'ceftazidime': 632, 'avibactam': 15, 'ceftolozane': 70, 'tazobactam': 1439, 'ceftriaxone in is-osm dextrose': 62, 'ceftriaxone sodium': 11025, 'cefuroxime axetil': 20691, 'celecoxib': 100516, 'cenegermin-bkbj': 175, 'cenobamate': 60, 'cephalexin': 109402, 'certolizumab pegol': 816, 'cetirizine hcl': 309, 'cevimeline hcl': 2021, 'chlorambucil': 32, 'chlordiazepoxide hcl': 2126, 'clidinium br': 721, 'chlorhexidine gluconate': 22728, 'chloroquine phosphate': 32, 'chlorothiazide': 35, 'chlorpromazine hcl': 5067, 'chlorzoxazone': 1356, 'cholestyramine (with sugar)': 7655, 'cholestyramine': 4068, 'aspartame': 4068, 'chorionic gonadotropin, human': 19, 'ciclesonide': 101, 'ciclopirox': 6017, 'ciclopirox olamine': 4638, 'cilostazol': 17752, 'cimetidine': 4085, 'cinacalcet hcl': 2815, 'ciprofloxacin': 153, 'ciprofloxacin hcl': 97016, 'dexameth': 3064, 'fluocinolone': 956, 'ciprofloxacin in 5 % dextrose': 55, 'hydrocortisone': 29348, 'citalopram hydrobromide': 157618, 'citric ac': 394, 'gluconolact': 65, 'mag carb': 65, 'citric acid': 29, 'sodium citrate': 29, 'cladribine': 48, 'clarithromycin': 6071, 'clemastine fumarate': 118, 'clindamycin hcl': 53308, 'clindamycin in 0.9 % sod chlor': 29, 'clindamycin palmitate hcl': 133, 'clindamycin phos': 211, 'benzoyl perox': 211, 'clindamycin phosphate': 6362, 'd5w': 13, 'clobazam': 1069, 'clobetasol propionate': 23406, 'emoll': 456, 'clocortolone pivalate': 23, 'clomiphene citrate': 94, 'clomipramine hcl': 1210, 'clonazepam': 238505, 'clonidine': 11535, 'clonidine hcl': 106196, 'clopidogrel bisulfate': 252428, 'clorazepate dipotassium': 4416, 'clotrimazole': 33272, 'betamethasone dip': 26823, 'clozapine': 9775, 'cobimetinib fumarate': 20, 'codeine sulfate': 114, 'asa': 515, 'caffein': 515, 'colchicine': 38578, 'colesevelam hcl': 9418, 'colestipol hcl': 10046, 'colistin (colistimethate na)': 77, 'collagenase clostridium hist.': 4813, 'corticotropin': 235, 'crisaborole': 298, 'crizotinib': 48, 'cromolyn sodium': 416, 'cyclobenzaprine hcl': 123102, 'cyclopentolate hcl': 203, 'cyclophosphamide': 115, 'cyclosporine': 23011, 'cyclosporine, modified': 873, 'cyproheptadine hcl': 8708, 'dabigatran etexilate mesylate': 10521, 'dabrafenib mesylate': 137, 'dalbavancin hcl': 547, 'dalfampridine': 1933, 'dalteparin sodium,porcine': 16, 'danazol': 160, 'dantrolene sodium': 1062, 'dapagliflozin propanediol': 17279, 'dapagliflozin': 2644, 'saxagliptin hcl': 5122, 'dapsone': 2102, 'daptomycin': 3140, 'daratumumab': 44, 'darbepoetin alfa in polysorbat': 73, 'darifenacin hydrobromide': 429, 'darolutamide': 204, 'darunavir ethanolate': 1941, 'darunavir': 3066, 'cob': 3715, 'emtri': 3715, 'tenof alaf': 1302, 'dasatinib': 654, 'decitabine': 28, 'cedazuridine': 28, 'deferasirox': 460, 'deferiprone': 16, 'delafloxacin meglumine': 14, 'demeclocycline hcl': 241, 'denosumab': 2815, 'desipramine hcl': 619, 'desloratadine': 3221, 'pseudoephedrine': 27, 'desmopressin (nonrefrigerated)': 525, 'desmopressin acetate': 2918, 'desog-e.estradiol': 86, 'e.estradiol': 86, 'desogestrel-ethinyl estradiol': 214, 'desonide': 2788, 'desoximetasone': 2494, 'desvenlafaxine': 85, 'desvenlafaxine succinate': 14500, 'deutetrabenazine': 2700, 'dexamethasone': 37928, 'dexamethasone sodium phosp': 23, 'pf': 69194, 'dexamethasone sodium phosphate': 2571, 'dexlansoprazole': 24903, 'dexmethylphenidate hcl': 1316, 'dextroamphetamine sulfate': 1719, 'dextroamphetamine': 58060, 'dextromethorphan hbr': 10002, 'quinidine': 10002, 'dextrose 5 % and 0.9 % nacl': 143, 'dextrose 5 % in water': 458, 'dextrose 5 %-0.45 % sod chlord': 457, 'dextrose 5%-lactated ringers': 55, 'diazepam': 55041, 'diazoxide': 25, 'diclofenac epolamine': 1786, 'diclofenac potassium': 3799, 'diclofenac sodium': 178058, 'misoprostol': 4650, 'diclofenac submicronized': 204, 'dicloxacillin sodium': 405, 'dicyclomine hcl': 54052, 'difenoxin hcl': 25, 'diflorasone diacetate': 271, 'diflunisal': 121, 'difluprednate': 7215, 'digoxin': 36695, 'dihydroergotamine mesylate': 149, 'diltiazem hcl': 133663, 'dimethyl fumarate': 1947, 'diph,pertuss(acell),tet vac': 1895, 'diphenhydramine hcl': 1144, 'diphenoxylate hcl': 17772, 'atropine': 17772, 'diphth,pertuss(acell),tet vac': 6808, 'diroximel fumarate': 49, 'disopyramide phosphate': 156, 'disulfiram': 209, 'divalproex sodium': 92950, 'dobutamine hcl': 50, 'docetaxel': 18, 'dofetilide': 2029, 'dolutegravir sodium': 6640, 'rilpivirine': 1183, 'donepezil hcl': 169127, 'doravirine': 266, 'lamivu': 39, 'tenofov diso': 20, 'dorzolamide hcl': 46182, 'timolol maleat': 33171, 'dorzolamide': 985, 'doxazosin mesylate': 34740, 'doxepin hcl': 33406, 'doxycycline hyclate': 105242, 'doxycycline monohydrate': 22759, 'dronabinol': 3589, 'dronedarone hcl': 9972, 'drospirenone': 360, 'estradiol': 101072, 'droxidopa': 402, 'dulaglutide': 60258, 'duloxetine hcl': 239759, 'dupilumab': 2576, 'durvalumab': 21, 'dutasteride': 15875, 'tamsulosin hcl': 271120, 'duvelisib': 25, 'econazole nitrate': 1405, 'eculizumab': 114, 'edaravone': 134, 'edoxaban tosylate': 154, 'efavirenz': 1433, 'tenofovr df': 865, 'tenofov disop': 19, 'efinaconazole': 437, 'elagolix sodium': 98, 'eletriptan hydrobromide': 1075, 'elexacaftor': 362, 'tezacaftor': 362, 'ivacaft': 362, 'eltrombopag olamine': 537, 'eluxadoline': 902, 'elviteg': 2413, 'tenof alafen': 2217, 'tenofo disop': 196, 'empaglifloz': 79, 'linaglip': 79, 'metformin': 79, 'empagliflozin': 54326, 'linagliptin': 27293, 'emtricita': 97, 'tenof df': 97, 'emtricitab': 1624, 'rilpiviri': 1624, 'tenof ala': 1624, 'emtricitabine': 6835, 'tenofov alafenam': 5297, 'tenofovir (tdf)': 1377, 'enalapril maleate': 37145, 'enalapril': 3772, 'enasidenib mesylate': 34, 'encorafenib': 65, 'enoxaparin sodium': 6085, 'entecavir': 629, 'enzalutamide': 3057, 'epinastine hcl': 912, 'epinephrine': 4426, 'eplerenone': 2503, 'epoetin alfa': 521, 'epoetin alfa-epbx': 309, 'erdafitinib': 11, 'erenumab-aooe': 7110, 'ergocalciferol (vitamin d2)': 100, 'ergotamine tartrate': 54, 'erlotinib hcl': 89, 'ertapenem sodium': 1983, 'ertugliflozin pidolate': 151, 'ertugliflozin': 39, 'sitagliptin': 39, 'erythromycin base': 14421, 'erythromycin base in ethanol': 218, 'erythromycin ethylsuccinate': 88, 'erythromycin stearate': 11, 'erythromycin': 63, 'escitalopram oxalate': 204852, 'esketamine hcl': 23, 'eslicarbazepine acetate': 2850, 'esomeprazole magnesium': 87784, 'estazolam': 76, 'estradiol acetate': 118, 'estradiol cypionate': 272, 'estradiol valerate': 149, 'levonorgestrel': 755, 'norethindrone acet': 2486, 'progesterone': 11, 'estrogen,con': 2176, 'm-progest acet': 2176, 'estrogens, conjugated': 17679, 'estrogens,conj': 165, 'bazedoxifene': 165, 'estrogens,esterified': 173, 'eszopiclone': 8241, 'etanercept': 5870, 'ethacrynic acid': 99, 'ethambutol hcl': 1179, 'ethinyl estradiol': 419, 'ethosuximide': 191, 'ethynodiol d-ethinyl estradiol': 67, 'etodolac': 8709, 'etonogestrel': 83, 'etoposide': 13, 'etravirine': 435, 'everolimus': 426, 'evolocumab': 14945, 'exemestane': 4756, 'exenatide': 464, 'exenatide microspheres': 8548, 'simvastatin': 293117, 'famciclovir': 3222, 'famotidine': 141559, 'fat emulsion': 230, 'olive': 230, 'soy': 230, 'phospho': 230, 'fat emulsions': 390, 'febuxostat': 8268, 'fedratinib dihydrochloride': 13, 'felbamate': 504, 'felodipine': 8609, 'fenofibrate': 50710, 'fenofibrate nanocrystallized': 30621, 'fenofibrate,micronized': 10047, 'fenofibric acid (choline)': 4625, 'fenoprofen calcium': 381, 'fentanyl': 24450, 'fentanyl citrate': 14, 'ferric citrate': 5543, 'fesoterodine fumarate': 5249, 'fidaxomicin': 178, 'filgrastim': 64, 'filgrastim-aafi': 19, 'filgrastim-sndz': 154, 'finasteride': 72213, 'fingolimod hcl': 1013, 'flavoxate hcl': 358, 'flecainide acetate': 23248, 'fluconazole': 104292, 'fluconazole in nacl,iso-osm': 62, 'fludrocortisone acetate': 8636, 'flunisolide': 846, 'fluocinolone acetonide': 1770, 'fluocinolone acetonide oil': 1672, 'shower cap': 943, 'fluocinonide': 10924, 'emollient base': 194, 'fluoride (sodium)': 1038, 'fluorometholone': 7115, 'fluorometholone acetate': 123, 'fluorouracil': 7102, 'fluoxetine hcl': 113667, 'fluphenazine decanoate': 3238, 'fluphenazine hcl': 4622, 'flurandrenolide': 85, 'flurazepam hcl': 75, 'flurbiprofen': 704, 'flurbiprofen sodium': 40, 'flutamide': 72, 'fluticasone furoate': 4643, 'fluticasone propion': 52680, 'salmeterol': 52680, 'fluticasone propionate': 226866, 'umeclidin': 49722, 'vilanter': 49722, 'vilanterol': 64148, 'fluvastatin sodium': 221, 'fluvoxamine maleate': 5173, 'folic acid': 1158, 'fondaparinux sodium': 71, 'fosamprenavir calcium': 56, 'fosaprepitant dimeglumine': 67, 'fosfomycin tromethamine': 390, 'fosinopril sodium': 10455, 'fosinopril': 753, 'fostamatinib disodium': 25, 'fremanezumab-vfrm': 896, 'frovatriptan succinate': 271, 'fulvestrant': 73, 'furosemide': 442838, 'gabapentin': 637491, 'gabapentin enacarbil': 467, 'galantamine hbr': 3373, 'galcanezumab-gnlm': 5006, 'ganciclovir': 178, 'gatifloxacin': 195, 'gemcitabine hcl': 58, 'gemfibrozil': 18835, 'gentamicin in nacl, iso-osm': 29, 'gentamicin sulfate': 8215, 'glatiramer acetate': 2057, 'glecaprevir': 300, 'pibrentasvir': 300, 'glimepiride': 124705, 'glipizide': 113863, 'glucagon': 458, 'glucagon hcl': 19, 'glucagon,human recombinant': 1930, 'glutamine': 43, 'glyburide': 4295, 'glyburide,micronized': 153, 'glycopyrrol': 91, 'nebulizer': 91, 'accessor': 91, 'glycopyrrolate': 7285, 'formoterol fum': 2269, 'neb.accessories': 293, 'glycopyrronium tosylate': 15, 'golimumab': 425, 'gr pol-orc': 12, 'sw ver': 12, 'rye': 12, 'kent': 12, 'tim': 12, 'granisetron': 235, 'granisetron hcl': 25, 'griseofulvin ultramicrosize': 54, 'griseofulvin, microsize': 238, 'guanfacine hcl': 2693, 'guselkumab': 279, 'haemoph b poly conj-tet tox': 16, 'halcinonide': 20, 'halobetasol propion': 54, 'tazarotene': 212, 'halobetasol propionate': 3505, 'haloperidol': 16592, 'haloperidol decanoate': 7925, 'haloperidol lactate': 1507, 'heparin sodium,porcine': 74, 'hepatitis a and b vaccine': 333, 'hepatitis a virus vaccine': 353, 'hepatitis b virus vaccine': 55, 'hpv vaccine 9-valent': 30, 'hydralazine hcl': 125840, 'hydrocodone bitartrate': 2270, 'hydrocodone': 855196, 'ibuprofen': 96313, 'hydrocortisone butyrate': 307, 'hydrocortisone sod succinate': 27, 'hydrocortisone sodium succ': 125, 'hydrocortisone valerate': 600, 'pramoxine': 118, 'hydromorphone hcl': 7954, 'hydroxychloroquine sulfate': 61680, 'hydroxyprogesterone caproat': 14, 'hydroxypropyl cellulose': 20, 'hydroxyurea': 7335, 'hydroxyzine hcl': 57645, 'hydroxyzine pamoate': 26282, 'hyoscyamine sulfate': 324, 'ibalizumab-uiyk': 25, 'ibandronate sodium': 10606, 'ibrutinib': 3527, 'icatibant acetate': 196, 'icosapent ethyl': 26566, 'idelalisib': 47, 'igg': 26, 'hyaluronidase,recombinant': 26, 'iloperidone': 633, 'imatinib mesylate': 2215, 'imipenem': 133, 'cilastatin sodium': 133, 'imipramine hcl': 5835, 'imipramine pamoate': 124, 'imiquimod': 1479, 'immun glob g(igg)-ifas': 271, 'glycine': 271, 'immun glob g(igg)': 4249, 'gly': 4768, 'iga 0-50': 2760, 'iga ov50': 1979, 'pro': 1564, 'immun glob g': 177, 'gluc': 11, 'sorb': 2668, 'immun globg(igg)': 313, 'malt': 313, 'immune globul g': 1906, 'iga avg 46': 1906, 'immune globulin,gamma(igg)klhw': 11, 'indapamide': 10090, 'indomethacin': 6393, 'infliximab': 396, 'infliximab-dyyb': 16, 'ingenol mebutate': 92, 'insulin admin. supplies': 15, 'insulin aspart': 44277, 'insulin aspart (niacinamide)': 597, 'insulin aspart prot': 10400, 'insuln asp': 10400, 'insulin degludec': 45177, 'liraglutide': 30876, 'insulin detemir': 53881, 'insulin glargine,hum.rec.anlog': 143427, 'insulin glargine': 3178, 'lixisenatide': 3178, 'insulin glulisine': 164, 'insulin lispro': 49252, 'insulin lispro protamin': 12337, 'lispro': 12337, 'insulin nph hum': 28459, 'reg insulin hm': 28459, 'insulin nph human isophane': 6646, 'insulin pump cartridge': 732, 'insulin regular, human': 13149, 'interferon alfa-2b,recomb.': 50, 'interferon beta-1a': 1869, 'albumin': 817, 'interferon beta-1b': 705, 'ipratropium bromide': 23183, 'ipratropium': 23557, 'irbesartan': 51410, 'irinotecan hcl': 13, 'isavuconazonium sulfate': 92, 'isoniazid': 247, 'isosorbide dinit': 2577, 'hydralazine': 2577, 'isosorbide dinitrate': 18105, 'isosorbide mononitrate': 92616, 'isotretinoin': 238, 'isradipine': 203, 'istradefylline': 129, 'itraconazole': 570, 'ivabradine hcl': 772, 'ivermectin': 2170, 'ivosidenib': 47, 'ixazomib citrate': 474, 'ixekizumab': 767, 'ketoconazole': 37614, 'ketoprofen': 57, 'ketorolac tromethamine': 19896, 'l-norgest': 120, 'e.estradiol-e.estrad': 120, 'labetalol hcl': 23345, 'lacosamide': 16827, 'lactulose': 27332, 'lamotrigine': 56930, 'lanadelumab-flyo': 158, 'lanreotide acetate': 78, 'lansoprazole': 21908, 'amoxiciln': 32, 'clarith': 32, 'lanthanum carbonate': 815, 'lapatinib ditosylate': 94, 'lasmiditan succinate': 78, 'latanoprost': 152209, 'latanoprostene bunod': 1661, 'ledipasvir': 162, 'sofosbuvir': 1317, 'leflunomide': 8568, 'lemborexant': 203, 'lenalidomide': 5328, 'lenvatinib mesylate': 328, 'letermovir': 13, 'letrozole': 18241, 'leucovorin calcium': 1484, 'leuprolide acetate': 376, 'levalbuterol hcl': 490, 'levalbuterol tartrate': 2574, 'levetiracetam': 81307, 'levobunolol hcl': 1297, 'levocarnitine': 250, 'levocarnitine (with sugar)': 25, 'levocetirizine dihydrochloride': 94190, 'levofloxacin': 66273, 'levofloxacin in dextrose 5 %': 346, 'levomilnacipran hcl': 1027, 'ethin.estradiol': 889, 'levorphanol tartrate': 122, 'levothyroxine sodium': 726442, 'lidocaine': 19498, 'lidocaine hcl': 13141, 'prilocaine': 5321, 'lifitegrast': 3428, 'linaclotide': 53074, 'lindane': 22, 'linezolid': 1471, 'linezolid in dextrose 5%': 145, 'liothyronine sodium': 6206, 'lipase': 8783, 'protease': 8783, 'amylase': 8783, 'lisdexamfetamine dimesylate': 5599, 'lisinopril': 650932, 'lithium carbonate': 16752, 'lithium citrate': 53, 'lodoxamide tromethamine': 20, 'lomustine': 19, 'loperamide hcl': 6348, 'lopinavir': 103, 'ritonavir': 2038, 'lorazepam': 140896, 'lorlatinib': 19, 'losartan potassium': 492334, 'losartan': 88251, 'loteprednol etabonate': 5074, 'lovastatin': 51318, 'loxapine succinate': 2745, 'lubiprostone': 15988, 'luliconazole': 11, 'lumateperone tosylate': 454, 'lurasidone hcl': 10956, 'macitentan': 1265, 'magnesium sulfate': 223, 'malathion': 36, 'maraviroc': 126, 'measles,mumps,rubella vacc': 493, 'mebendazole': 24, 'mecamylamine hcl': 16, 'mechlorethamine hcl': 24, 'meclizine hcl': 60256, 'medroxyprogesterone acetate': 10692, 'mefloquine hcl': 32, 'megestrol acetate': 11319, 'meloxicam': 316684, 'meloxicam, submicronized': 20, 'memantine hcl': 115594, 'mening vac a,c,y,w-135 dip': 67, 'meningococcal b vaccine,4-comp': 23, 'meperidine hcl': 92, 'mepolizumab': 307, 'meprobamate': 48, 'mercaptopurine': 527, 'meropenem': 2585, 'meropenem-0.9% sodium chloride': 118, 'mesalamine': 8723, 'mesalamine w': 72, 'cleansing wipes': 72, 'metaxalone': 1436, 'methadone hcl': 16385, 'methamphetamine hcl': 50, 'methazolamide': 454, 'methenam': 35, 'sod phos': 35, 'mblue': 35, 'hyoscy': 35, 'methenamine hippurate': 7327, 'methenamine mandelate': 75, 'methimazole': 10119, 'methocarbamol': 63259, 'methotrexate sodium': 48076, 'methotrexate': 808, 'methscopolamine bromide': 1545, 'methsuximide': 20, 'methyldopa': 280, 'methylnaltrexone bromide': 1298, 'methylphenidate': 11, 'methylphenidate hcl': 12245, 'methylprednisolone': 116192, 'methylprednisolone acetate': 513, 'methylprednisolone sod succ': 760, 'metoclopramide hcl': 30924, 'metolazone': 18114, 'metoprolol succinate': 377123, 'metoprolol tartrate': 234257, 'metoprolol': 777, 'metreleptin': 11, 'metronidazole': 39699, 'sodium chloride': 7855, 'mexiletine hcl': 870, 'micafungin sodium': 158, 'miconazole nitrate': 26, 'zinc ox': 12, 'pet': 12, 'midazolam': 47, 'midazolam hcl': 19, 'midodrine hcl': 14930, 'midostaurin': 17, 'mifepristone': 77, 'miglitol': 14, 'milnacipran hcl': 2456, 'minocycline hcl': 7973, 'minoxidil': 5608, 'mirabegron': 57973, 'mirtazapine': 139025, 'modafinil': 6102, 'moexipril hcl': 1105, 'mometasone furoate': 16825, 'mometasone': 8020, 'montelukast sodium': 275157, 'morphine sulfate': 51087, 'naltrexone': 45, 'moxifloxacin hcl': 5668, 'multivit-mins60': 20, 'iron fum': 213, 'folic': 98, 'mupirocin': 61771, 'mupirocin calcium': 1091, 'mvn-min75': 17, 'iron': 800, 'iron ps': 17, 'om3': 201, 'dha': 51, 'mycophenolate mofetil': 6183, 'mycophenolate sodium': 605, 'nabumetone': 12239, 'nadolol': 6768, 'nafcillin sodium': 214, 'naftifine hcl': 294, 'naldemedine tosylate': 550, 'naloxegol oxalate': 3979, 'naltrexone hcl': 2044, 'naltrexone microspheres': 70, 'naproxen': 56555, 'naproxen sodium': 2298, 'esomeprazole mag': 64, 'naratriptan hcl': 1745, 'natalizumab': 51, 'natamycin': 48, 'nateglinide': 2300, 'nebivolol hcl': 33806, 'nefazodone hcl': 494, 'neomyc': 211, 'colist': 211, 'hydrocort': 10618, 'thonzn': 211, 'neomycin sulf': 201, 'poly': 127, 'polymyxin b sulf': 5785, 'neomycin sulfate': 1221, 'neomycin': 22549, 'bacit': 112, 'p-myx': 112, 'polymyxin b': 22332, 'dexametha': 12037, 'polymyxn b': 105, 'gramicidin': 105, 'nepafenac': 2012, 'neratinib maleate': 113, 'netarsudil mesylat': 1207, 'netarsudil mesylate': 1859, 'nevirapine': 200, 'niacin': 4800, 'nicardipine hcl': 78, 'nicotine': 313, 'nifedipine': 41486, 'nilotinib hcl': 629, 'nilutamide': 12, 'nimodipine': 20, 'nintedanib esylate': 1781, 'niraparib tosylate': 146, 'nisoldipine': 501, 'nitazoxanide': 121, 'nitrofurantoin': 36, 'nitrofurantoin macrocrystal': 19487, 'nitrofurantoin monohyd': 63210, 'm-cryst': 63210, 'nitroglycerin': 48003, 'nivolumab': 41, 'nizatidine': 187, 'norelgestromin': 186, 'noreth-ethinyl estradiol': 16, 'norethindrone': 1033, 'norethindrone ac-eth estradiol': 708, 'norethindrone acetate': 1283, 'norethindrone-e.estradiol-iron': 1241, 'norethindrone-ethin. estradiol': 528, 'norgestimate-ethinyl estradiol': 2129, 'norgestrel-ethinyl estradiol': 387, 'nortriptyline hcl': 25205, 'nystatin': 68035, 'triamcin': 6033, 'obeticholic acid': 140, 'ocrelizumab': 106, 'octreotide acetate': 116, 'octreotide acetate,mi-spheres': 120, 'ofloxacin': 24717, 'olanzapine': 54841, 'olanzapine pamoate': 42, 'olaparib': 295, 'olmesartan medoxomil': 30079, 'olmesartan': 16610, 'amlodipin': 2156, 'olodaterol hcl': 8223, 'olopatadine hcl': 17056, 'olsalazine sodium': 18, 'omadacycline tosylate': 43, 'omalizumab': 767, 'omega-3 acid ethyl esters': 12767, 'omeprazole': 529881, 'omeprazole magnesium': 122, 'amoxicill': 39, 'rifabutin': 121, 'sodium bicarbonate': 730, 'onabotulinumtoxina': 568, 'ondansetron': 47178, 'ondansetron hcl': 96609, 'opium tincture': 33, 'oritavancin diphosphate': 16, 'orphenadrine citrate': 658, 'oseltamivir phosphate': 13647, 'osimertinib mesylate': 611, 'ospemifene': 588, 'oxaliplatin': 40, 'oxaprozin': 583, 'oxazepam': 1512, 'oxcarbazepine': 28991, 'oxiconazole nitrate': 48, 'oxybutynin chloride': 96395, 'oxycodone hcl': 362561, 'oxycodone myristate': 8423, 'oxymetazoline hcl': 31, 'oxymorphone hcl': 1417, 'paclitaxel': 39, 'palbociclib': 2171, 'paliperidone': 6394, 'paliperidone palmitate': 14503, 'palonosetron hcl': 102, 'panobinostat lactate': 13, 'pantoprazole sodium': 480864, 'parenteral amino acid 10% no.6': 11, 'parenteral amino acid 15% no.5': 65, 'parenteral amino acid 20% no.1': 2210, 'paricalcitol': 1156, 'paroxetine hcl': 72118, 'paroxetine mesylate': 129, 'patiromer calcium sorbitex': 1211, 'pazopanib hcl': 157, 'peg3350': 10293, 'sod sul': 1831, 'nacl': 1831, 'kcl': 18084, 'asb': 1831, 'c': 1831, 'sod sulf,bicarb,cl': 8462, 'pegfilgrastim': 128, 'peginterferon beta-1a': 175, 'pegloticase': 83, 'pegvisomant': 42, 'pembrolizumab': 59, 'pemetrexed disodium': 12, 'pen needle, diabetic': 106386, 'pen needle, diabetic, safety': 1797, 'pen needle,dual safety,diabetc': 1995, 'penciclovir': 60, 'penicillin g benzathine': 16, 'penicillin g potassium': 78, 'penicillin v potassium': 7877, 'pentazocine hcl': 598, 'pentosan polysulfate sodium': 1226, 'pentoxifylline': 7517, 'perampanel': 1076, 'perindopril erbumine': 428, 'permethrin': 3373, 'perphenazine': 3442, 'pertuzumab': 21, 'phenazopyridine hcl': 2046, 'phenelzine sulfate': 144, 'phenobarbital': 11057, 'phenytoin': 3027, 'phenytoin sodium extended': 22841, 'pilocarpine hcl': 5793, 'pimavanserin tartrate': 2996, 'pimecrolimus': 562, 'pimozide': 158, 'pindolol': 1084, 'pioglitazone hcl': 55882, 'piperacillin sodium': 1369, 'piperacillin-tazo-dextrose,iso': 17, 'pirfenidone': 990, 'piroxicam': 1498, 'pitavastatin calcium': 8546, 'pitolisant hcl': 78, 'plecanatide': 2740, 'pnv 11': 163, 'pnv 112': 21, 'epa': 21, 'pnv 119': 19, 'pnv no.162': 18, 'iron glu': 18, 'pnv,calcium 72': 559, 'iron,carb': 14, 'podofilox': 80, 'poliomyelitis vaccine, killed': 17, 'polyethylene glycol 3350': 405, 'trimethoprim': 113842, 'pomalidomide': 1431, 'ponatinib hcl': 55, 'posaconazole': 96, 'potassium bicarbonate': 76, 'cit ac': 76, 'potassium chloride': 405945, 'potassium chloride in 0.9%nacl': 16, 'potassium chloride-0.45% nacl': 11, 'd5-0.45nacl': 14, 'potassium citrate': 6446, 'potassium phosphate,monobasic': 40, 'pramipexole di-hcl': 44242, 'pramlintide acetate': 77, 'prasterone (dhea)': 363, 'prasugrel hcl': 11289, 'pravastatin sodium': 276675, 'praziquantel': 14, 'prazosin hcl': 11802, 'prednicarbate': 21, 'prednisolone': 380, 'prednisolone acetate': 41027, 'prednisolone sodium phosphate': 297, 'prednisone': 225931, 'pregabalin': 150243, 'prenatal 147': 154, 'prenatal vit 10': 24, 'prenatal vit,calc76': 19, 'prenatal vit27,calcium': 15, 'fa': 15, 'primidone': 32518, 'probenecid': 2680, 'prochlorperazine': 568, 'prochlorperazine maleate': 7934, 'progesterone, micronized': 6049, 'promethazine hcl': 61484, 'propafenone hcl': 5282, 'propantheline bromide': 19, 'propranolol hcl': 53329, 'propranolol': 34, 'propylthiouracil': 709, 'protriptyline hcl': 139, 'prucalopride succinate': 648, 'pyridostigmine bromide': 5437, 'pyrimethamine': 68, 'quetiapine fumarate': 166376, 'quinapril hcl': 14767, 'quinapril': 1675, 'quinidine gluconate': 70, 'quinidine sulfate': 55, 'quinine sulfate': 56, 'rabeprazole sodium': 3601, 'raloxifene hcl': 18579, 'raltegravir potassium': 1702, 'ramelteon': 1235, 'ramipril': 49934, 'ranitidine hcl': 15127, 'ranolazine': 34492, 'rasagiline mesylate': 2733, 'regorafenib': 132, 'repaglinide': 2504, 'ribavirin': 23, 'ribociclib succinate': 546, 'rifampin': 1865, 'rifaximin': 5478, 'rilpivirine hcl': 159, 'riluzole': 380, 'rimegepant sulfate': 364, \"ringer's solution,lactated\": 84, 'riociguat': 499, 'risankizumab-rzaa': 261, 'risedronate sodium': 4655, 'risperidone': 60465, 'risperidone microspheres': 4059, 'rituximab': 70, 'rivaroxaban': 113724, 'rivastigmine': 10203, 'rivastigmine tartrate': 8826, 'rizatriptan benzoate': 17487, 'roflumilast': 6870, 'romosozumab-aqqg': 50, 'ropinirole hcl': 85300, 'rosiglitazone maleate': 16, 'rosuvastatin calcium': 256346, 'rotigotine': 2813, 'rucaparib camsylate': 80, 'rufinamide': 380, 'ruxolitinib phosphate': 1580, 'sacrosidase': 56, 'sacubitril': 34003, 'safinamide mesylate': 100, 'salmeterol xinafoate': 714, 'salsalate': 267, 'sarilumab': 365, 'scopolamine': 3103, 'secukinumab': 2766, 'selegiline': 44, 'selegiline hcl': 778, 'selenium sulfide': 426, 'selexipag': 347, 'selinexor': 21, 'semaglutide': 40242, 'sertraline hcl': 203320, 'sevelamer carbonate': 14522, 'sevelamer hcl': 219, 'sildenafil citrate': 4356, 'silodosin': 3672, 'silver sulfadiazine': 9591, 'siponimod': 77, 'sirolimus': 299, 'sitagliptin phos': 30627, 'sitagliptin phosphate': 88026, 'sod phosphate mbas': 17, 'sod phos,di': 17, 'sod picosulf': 329, 'mag ox': 329, 'sodium chloride 0.45 %': 960, 'sodium chloride irrig solution': 457, 'nahco3': 7791, 'peg': 7791, 'sodium fluoride': 170, 'potassium nit': 170, 'sodium oxybate': 413, 'sodium polystyrene sulfon': 2502, 'sodium polystyrene sulfonate': 783, 'sodium zirconium cyclosilicate': 742, 'sodium, potassium,mag sulfates': 14634, 'velpatas': 29, 'voxilaprev': 29, 'velpatasvir': 1126, 'solifenacin succinate': 11867, 'solriamfetol hcl': 226, 'somatropin': 260, 'sonidegib phosphate': 26, 'sorafenib tosylate': 55, 'sotalol hcl': 26946, 'spironolact': 5998, 'spironolactone': 113954, 'streptomycin sulfate': 101, 'sub-q insulin device, 20 unit': 64, 'sub-q insulin device, 30 unit': 89, 'sub-q insulin device, 40 unit': 134, 'sucralfate': 70203, 'sucroferric oxyhydroxide': 2225, 'sulfacetamide sodium': 905, 'sulfacetamide': 374, 'prednisolone sp': 327, 'sulfadiazine': 63, 'sulfamethoxazole': 101658, 'sulfasalazine': 9059, 'sulindac': 2834, 'sumatriptan': 417, 'sumatriptan succ': 150, 'naproxen sod': 150, 'sumatriptan succinate': 30359, 'sunitinib malate': 160, 'suvorexant': 5794, 'syrge-ndl,ins 0.3 ml half mark': 602, 'syrge-ndl,ins 0.5 ml half mark': 341, 'syring-needl,disp,insul,0.3 ml': 4642, 'syringe and needle,insulin,1ml': 14114, 'syringe with needle, insulin': 92, 'syringe,insul u-500,ndl,0.5ml': 88, 'syringe,needle,insuln,safe,1ml': 104, 'syringe,needle,insuln,sf 0.5ml': 15, 'syringe-needle,insulin,0.5 ml': 11839, 'tacrolimus': 4966, 'tadalafil': 5368, 'tafamidis': 86, 'tafamidis meglumine': 71, 'tafluprost': 860, 'tamoxifen citrate': 6180, 'tapentadol hcl': 4390, 'tasimelteon': 79, 'tbo-filgrastim': 34, 'tedizolid phosphate': 17, 'teduglutide': 132, 'tegaserod hydrogen maleate': 44, 'telavancin hcl': 47, 'telmisartan': 39605, 'telotristat etiprate': 41, 'temazepam': 55224, 'temozolomide': 34, 'tenofovir alafenamide': 764, 'tenofovir disoproxil fumarate': 1241, 'teprotumumab-trbw': 71, 'terazosin hcl': 21750, 'terbinafine hcl': 13066, 'terbutaline sulfate': 195, 'terconazole': 2822, 'teriflunomide': 1162, 'teriparatide': 1774, 'tesamorelin acetate': 11, 'testosterone': 4514, 'testosterone cypionate': 21006, 'testosterone enanthate': 414, 'tetanus, diphtheria tox,adult': 44, 'tetanus-diphtheria toxoids': 365, 'tetrabenazine': 715, 'tetracycline hcl': 559, 'thalidomide': 88, 'theophylline anhydrous': 9478, 'thioridazine hcl': 719, 'thiothixene': 396, 'thyroid,pork': 4720, 'tiagabine hcl': 856, 'ticagrelor': 19747, 'tigecycline': 34, 'tildrakizumab-asmn': 13, 'timolol maleate': 38183, 'tinidazole': 106, 'tiopronin': 59, 'tiotropium br': 8206, 'tiotropium bromide': 37719, 'tipranavir': 14, 'tizanidine hcl': 228002, 'tobramycin': 12414, 'tobramycin in 0.225% sod chlor': 18, 'tobramycin sulfate': 511, 'lotepred etab': 270, 'tocilizumab': 953, 'tofacitinib citrate': 3225, 'tolcapone': 12, 'tolterodine tartrate': 20689, 'tolvaptan': 126, 'topiramate': 65239, 'torsemide': 36805, 'tramadol hcl': 352431, 'trametinib dimethyl sulfoxide': 145, 'trandolapril': 3008, 'verapamil hcl': 35853, 'tranexamic acid': 218, 'tranylcypromine sulfate': 40, 'trastuzumab': 33, 'travoprost': 16246, 'trazodone hcl': 327046, 'treprostinil diolamine': 328, 'treprostinil': 15, 'neb accessories': 15, 'tretinoin': 1832, 'tretinoin microspheres': 69, 'triamcinolone acetonide': 79927, 'triamterene': 78435, 'triazolam': 1127, 'trientine hcl': 12, 'trifluoperazine hcl': 313, 'trifluridine': 422, 'tipiracil hcl': 138, 'trihexyphenidyl hcl': 4905, 'trimethobenzamide hcl': 65, 'trimipramine maleate': 39, 'triptorelin pamoate': 11, 'trospium chloride': 3486, 'typhoid vi polysacch vaccine': 14, 'ubrogepant': 993, 'umeclidinium brm': 38808, 'vilanterol tr': 38808, 'umeclidinium bromide': 16370, 'upadacitinib': 1398, 'ursodiol': 4843, 'ustekinumab': 938, 'valacyclovir hcl': 52580, 'valbenazine tosylate': 2006, 'valganciclovir hcl': 1144, 'valproic acid': 1770, 'valproic acid (as sodium salt)': 4317, 'vancomycin hcl': 8623, 'vancomycin': 70, '0.9 % sod chloride': 33, 'water for inj (peg)': 37, 'vandetanib': 27, 'varenicline tartrate': 10620, 'varicella-zoster ge': 56523, 'as01b': 56523, 'vedolizumab': 250, 'vemurafenib': 28, 'venetoclax': 808, 'venlafaxine hcl': 97960, 'vigabatrin': 49, 'vilazodone hcl': 6648, 'vismodegib': 220, 'vorapaxar sulfate': 50, 'voriconazole': 773, 'vorinostat': 13, 'vortioxetine hydrobromide': 11827, 'voxelotor': 192, 'warfarin sodium': 96012, 'water for irrigation,sterile': 43, 'weed pollen-short ragweed': 12, 'zafirlukast': 1758, 'zaleplon': 2444, 'zileuton': 79, 'ziprasidone hcl': 17982, 'ziprasidone mesylate': 184, 'zoledronic ac': 24, 'mannitol': 24, '0.9nacl': 24, 'zoledronic acid': 134, 'mannitol-water': 134, 'zolmitriptan': 1227, 'zolpidem tartrate': 162605, 'zonisamide': 8546, 'zoster vaccine live': 30}\n"
     ]
    }
   ],
   "source": [
    "import csv\n",
    "\n",
    "place_array = []\n",
    "\n",
    "# opening the CSV file\n",
    "with open('usa.csv', mode='r') as file:\n",
    "    # reading the CSV file\n",
    "    csvFile = csv.DictReader(file)\n",
    "\n",
    "    # displaying the contents of the CSV file\n",
    "    for lines in csvFile:\n",
    "        place = lines['Prscrbr_Geo_Desc']\n",
    "        if (place not in place_array):\n",
    "            place_array.append(place)\n",
    "\n",
    "print(place_array)\n",
    "state = input(\"Enter the state name : \")\n",
    "\n",
    "if (state not in  place_array):\n",
    "    print(\"State not found\")\n",
    "else:\n",
    "    dict1 = sales(state)\n",
    "\n",
    "\n",
    "print(dict1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 209,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[209], line 21\u001b[0m\n\u001b[0;32m     18\u001b[0m plt\u001b[39m.\u001b[39mtitle(\u001b[39m'\u001b[39m\u001b[39mGraph\u001b[39m\u001b[39m'\u001b[39m)\n\u001b[0;32m     20\u001b[0m \u001b[39m# function to show the plot\u001b[39;00m\n\u001b[1;32m---> 21\u001b[0m plt\u001b[39m.\u001b[39;49mshow()\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\pyplot.py:446\u001b[0m, in \u001b[0;36mshow\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    402\u001b[0m \u001b[39m\u001b[39m\u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    403\u001b[0m \u001b[39mDisplay all open figures.\u001b[39;00m\n\u001b[0;32m    404\u001b[0m \n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    443\u001b[0m \u001b[39mexplicitly there.\u001b[39;00m\n\u001b[0;32m    444\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    445\u001b[0m _warn_if_gui_out_of_main_thread()\n\u001b[1;32m--> 446\u001b[0m \u001b[39mreturn\u001b[39;00m _get_backend_mod()\u001b[39m.\u001b[39;49mshow(\u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\matplotlib_inline\\backend_inline.py:90\u001b[0m, in \u001b[0;36mshow\u001b[1;34m(close, block)\u001b[0m\n\u001b[0;32m     88\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m     89\u001b[0m     \u001b[39mfor\u001b[39;00m figure_manager \u001b[39min\u001b[39;00m Gcf\u001b[39m.\u001b[39mget_all_fig_managers():\n\u001b[1;32m---> 90\u001b[0m         display(\n\u001b[0;32m     91\u001b[0m             figure_manager\u001b[39m.\u001b[39;49mcanvas\u001b[39m.\u001b[39;49mfigure,\n\u001b[0;32m     92\u001b[0m             metadata\u001b[39m=\u001b[39;49m_fetch_figure_metadata(figure_manager\u001b[39m.\u001b[39;49mcanvas\u001b[39m.\u001b[39;49mfigure)\n\u001b[0;32m     93\u001b[0m         )\n\u001b[0;32m     94\u001b[0m \u001b[39mfinally\u001b[39;00m:\n\u001b[0;32m     95\u001b[0m     show\u001b[39m.\u001b[39m_to_draw \u001b[39m=\u001b[39m []\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\IPython\\core\\display_functions.py:298\u001b[0m, in \u001b[0;36mdisplay\u001b[1;34m(include, exclude, metadata, transient, display_id, raw, clear, *objs, **kwargs)\u001b[0m\n\u001b[0;32m    296\u001b[0m     publish_display_data(data\u001b[39m=\u001b[39mobj, metadata\u001b[39m=\u001b[39mmetadata, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs)\n\u001b[0;32m    297\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[1;32m--> 298\u001b[0m     format_dict, md_dict \u001b[39m=\u001b[39m \u001b[39mformat\u001b[39;49m(obj, include\u001b[39m=\u001b[39;49minclude, exclude\u001b[39m=\u001b[39;49mexclude)\n\u001b[0;32m    299\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39mnot\u001b[39;00m format_dict:\n\u001b[0;32m    300\u001b[0m         \u001b[39m# nothing to display (e.g. _ipython_display_ took over)\u001b[39;00m\n\u001b[0;32m    301\u001b[0m         \u001b[39mcontinue\u001b[39;00m\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\IPython\\core\\formatters.py:177\u001b[0m, in \u001b[0;36mDisplayFormatter.format\u001b[1;34m(self, obj, include, exclude)\u001b[0m\n\u001b[0;32m    175\u001b[0m md \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m\n\u001b[0;32m    176\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m--> 177\u001b[0m     data \u001b[39m=\u001b[39m formatter(obj)\n\u001b[0;32m    178\u001b[0m \u001b[39mexcept\u001b[39;00m:\n\u001b[0;32m    179\u001b[0m     \u001b[39m# FIXME: log the exception\u001b[39;00m\n\u001b[0;32m    180\u001b[0m     \u001b[39mraise\u001b[39;00m\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\decorator.py:232\u001b[0m, in \u001b[0;36mdecorate.<locals>.fun\u001b[1;34m(*args, **kw)\u001b[0m\n\u001b[0;32m    230\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mnot\u001b[39;00m kwsyntax:\n\u001b[0;32m    231\u001b[0m     args, kw \u001b[39m=\u001b[39m fix(args, kw, sig)\n\u001b[1;32m--> 232\u001b[0m \u001b[39mreturn\u001b[39;00m caller(func, \u001b[39m*\u001b[39;49m(extras \u001b[39m+\u001b[39;49m args), \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkw)\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\IPython\\core\\formatters.py:221\u001b[0m, in \u001b[0;36mcatch_format_error\u001b[1;34m(method, self, *args, **kwargs)\u001b[0m\n\u001b[0;32m    219\u001b[0m \u001b[39m\u001b[39m\u001b[39m\"\"\"show traceback on failed format call\"\"\"\u001b[39;00m\n\u001b[0;32m    220\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m--> 221\u001b[0m     r \u001b[39m=\u001b[39m method(\u001b[39mself\u001b[39;49m, \u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[0;32m    222\u001b[0m \u001b[39mexcept\u001b[39;00m \u001b[39mNotImplementedError\u001b[39;00m:\n\u001b[0;32m    223\u001b[0m     \u001b[39m# don't warn on NotImplementedErrors\u001b[39;00m\n\u001b[0;32m    224\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_check_return(\u001b[39mNone\u001b[39;00m, args[\u001b[39m0\u001b[39m])\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\IPython\\core\\formatters.py:338\u001b[0m, in \u001b[0;36mBaseFormatter.__call__\u001b[1;34m(self, obj)\u001b[0m\n\u001b[0;32m    336\u001b[0m     \u001b[39mpass\u001b[39;00m\n\u001b[0;32m    337\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[1;32m--> 338\u001b[0m     \u001b[39mreturn\u001b[39;00m printer(obj)\n\u001b[0;32m    339\u001b[0m \u001b[39m# Finally look for special method names\u001b[39;00m\n\u001b[0;32m    340\u001b[0m method \u001b[39m=\u001b[39m get_real_method(obj, \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mprint_method)\n",
      "File \u001b[1;32m~\\AppData\\Roaming\\Python\\Python311\\site-packages\\IPython\\core\\pylabtools.py:152\u001b[0m, in \u001b[0;36mprint_figure\u001b[1;34m(fig, fmt, bbox_inches, base64, **kwargs)\u001b[0m\n\u001b[0;32m    149\u001b[0m     \u001b[39mfrom\u001b[39;00m \u001b[39mmatplotlib\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mbackend_bases\u001b[39;00m \u001b[39mimport\u001b[39;00m FigureCanvasBase\n\u001b[0;32m    150\u001b[0m     FigureCanvasBase(fig)\n\u001b[1;32m--> 152\u001b[0m fig\u001b[39m.\u001b[39;49mcanvas\u001b[39m.\u001b[39;49mprint_figure(bytes_io, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkw)\n\u001b[0;32m    153\u001b[0m data \u001b[39m=\u001b[39m bytes_io\u001b[39m.\u001b[39mgetvalue()\n\u001b[0;32m    154\u001b[0m \u001b[39mif\u001b[39;00m fmt \u001b[39m==\u001b[39m \u001b[39m'\u001b[39m\u001b[39msvg\u001b[39m\u001b[39m'\u001b[39m:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\backend_bases.py:2342\u001b[0m, in \u001b[0;36mFigureCanvasBase.print_figure\u001b[1;34m(self, filename, dpi, facecolor, edgecolor, orientation, format, bbox_inches, pad_inches, bbox_extra_artists, backend, **kwargs)\u001b[0m\n\u001b[0;32m   2336\u001b[0m     renderer \u001b[39m=\u001b[39m _get_renderer(\n\u001b[0;32m   2337\u001b[0m         \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mfigure,\n\u001b[0;32m   2338\u001b[0m         functools\u001b[39m.\u001b[39mpartial(\n\u001b[0;32m   2339\u001b[0m             print_method, orientation\u001b[39m=\u001b[39morientation)\n\u001b[0;32m   2340\u001b[0m     )\n\u001b[0;32m   2341\u001b[0m     \u001b[39mwith\u001b[39;00m \u001b[39mgetattr\u001b[39m(renderer, \u001b[39m\"\u001b[39m\u001b[39m_draw_disabled\u001b[39m\u001b[39m\"\u001b[39m, nullcontext)():\n\u001b[1;32m-> 2342\u001b[0m         \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mfigure\u001b[39m.\u001b[39;49mdraw(renderer)\n\u001b[0;32m   2344\u001b[0m \u001b[39mif\u001b[39;00m bbox_inches:\n\u001b[0;32m   2345\u001b[0m     \u001b[39mif\u001b[39;00m bbox_inches \u001b[39m==\u001b[39m \u001b[39m\"\u001b[39m\u001b[39mtight\u001b[39m\u001b[39m\"\u001b[39m:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\artist.py:95\u001b[0m, in \u001b[0;36m_finalize_rasterization.<locals>.draw_wrapper\u001b[1;34m(artist, renderer, *args, **kwargs)\u001b[0m\n\u001b[0;32m     93\u001b[0m \u001b[39m@wraps\u001b[39m(draw)\n\u001b[0;32m     94\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mdraw_wrapper\u001b[39m(artist, renderer, \u001b[39m*\u001b[39margs, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs):\n\u001b[1;32m---> 95\u001b[0m     result \u001b[39m=\u001b[39m draw(artist, renderer, \u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[0;32m     96\u001b[0m     \u001b[39mif\u001b[39;00m renderer\u001b[39m.\u001b[39m_rasterizing:\n\u001b[0;32m     97\u001b[0m         renderer\u001b[39m.\u001b[39mstop_rasterizing()\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\artist.py:72\u001b[0m, in \u001b[0;36mallow_rasterization.<locals>.draw_wrapper\u001b[1;34m(artist, renderer)\u001b[0m\n\u001b[0;32m     69\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n\u001b[0;32m     70\u001b[0m         renderer\u001b[39m.\u001b[39mstart_filter()\n\u001b[1;32m---> 72\u001b[0m     \u001b[39mreturn\u001b[39;00m draw(artist, renderer)\n\u001b[0;32m     73\u001b[0m \u001b[39mfinally\u001b[39;00m:\n\u001b[0;32m     74\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\figure.py:3140\u001b[0m, in \u001b[0;36mFigure.draw\u001b[1;34m(self, renderer)\u001b[0m\n\u001b[0;32m   3137\u001b[0m         \u001b[39m# ValueError can occur when resizing a window.\u001b[39;00m\n\u001b[0;32m   3139\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mpatch\u001b[39m.\u001b[39mdraw(renderer)\n\u001b[1;32m-> 3140\u001b[0m mimage\u001b[39m.\u001b[39;49m_draw_list_compositing_images(\n\u001b[0;32m   3141\u001b[0m     renderer, \u001b[39mself\u001b[39;49m, artists, \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49msuppressComposite)\n\u001b[0;32m   3143\u001b[0m \u001b[39mfor\u001b[39;00m sfig \u001b[39min\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39msubfigs:\n\u001b[0;32m   3144\u001b[0m     sfig\u001b[39m.\u001b[39mdraw(renderer)\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\image.py:131\u001b[0m, in \u001b[0;36m_draw_list_compositing_images\u001b[1;34m(renderer, parent, artists, suppress_composite)\u001b[0m\n\u001b[0;32m    129\u001b[0m \u001b[39mif\u001b[39;00m not_composite \u001b[39mor\u001b[39;00m \u001b[39mnot\u001b[39;00m has_images:\n\u001b[0;32m    130\u001b[0m     \u001b[39mfor\u001b[39;00m a \u001b[39min\u001b[39;00m artists:\n\u001b[1;32m--> 131\u001b[0m         a\u001b[39m.\u001b[39;49mdraw(renderer)\n\u001b[0;32m    132\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[0;32m    133\u001b[0m     \u001b[39m# Composite any adjacent images together\u001b[39;00m\n\u001b[0;32m    134\u001b[0m     image_group \u001b[39m=\u001b[39m []\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\artist.py:72\u001b[0m, in \u001b[0;36mallow_rasterization.<locals>.draw_wrapper\u001b[1;34m(artist, renderer)\u001b[0m\n\u001b[0;32m     69\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n\u001b[0;32m     70\u001b[0m         renderer\u001b[39m.\u001b[39mstart_filter()\n\u001b[1;32m---> 72\u001b[0m     \u001b[39mreturn\u001b[39;00m draw(artist, renderer)\n\u001b[0;32m     73\u001b[0m \u001b[39mfinally\u001b[39;00m:\n\u001b[0;32m     74\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axes\\_base.py:3064\u001b[0m, in \u001b[0;36m_AxesBase.draw\u001b[1;34m(self, renderer)\u001b[0m\n\u001b[0;32m   3061\u001b[0m \u001b[39mif\u001b[39;00m artists_rasterized:\n\u001b[0;32m   3062\u001b[0m     _draw_rasterized(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mfigure, artists_rasterized, renderer)\n\u001b[1;32m-> 3064\u001b[0m mimage\u001b[39m.\u001b[39;49m_draw_list_compositing_images(\n\u001b[0;32m   3065\u001b[0m     renderer, \u001b[39mself\u001b[39;49m, artists, \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mfigure\u001b[39m.\u001b[39;49msuppressComposite)\n\u001b[0;32m   3067\u001b[0m renderer\u001b[39m.\u001b[39mclose_group(\u001b[39m'\u001b[39m\u001b[39maxes\u001b[39m\u001b[39m'\u001b[39m)\n\u001b[0;32m   3068\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mstale \u001b[39m=\u001b[39m \u001b[39mFalse\u001b[39;00m\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\image.py:131\u001b[0m, in \u001b[0;36m_draw_list_compositing_images\u001b[1;34m(renderer, parent, artists, suppress_composite)\u001b[0m\n\u001b[0;32m    129\u001b[0m \u001b[39mif\u001b[39;00m not_composite \u001b[39mor\u001b[39;00m \u001b[39mnot\u001b[39;00m has_images:\n\u001b[0;32m    130\u001b[0m     \u001b[39mfor\u001b[39;00m a \u001b[39min\u001b[39;00m artists:\n\u001b[1;32m--> 131\u001b[0m         a\u001b[39m.\u001b[39;49mdraw(renderer)\n\u001b[0;32m    132\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[0;32m    133\u001b[0m     \u001b[39m# Composite any adjacent images together\u001b[39;00m\n\u001b[0;32m    134\u001b[0m     image_group \u001b[39m=\u001b[39m []\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\artist.py:72\u001b[0m, in \u001b[0;36mallow_rasterization.<locals>.draw_wrapper\u001b[1;34m(artist, renderer)\u001b[0m\n\u001b[0;32m     69\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n\u001b[0;32m     70\u001b[0m         renderer\u001b[39m.\u001b[39mstart_filter()\n\u001b[1;32m---> 72\u001b[0m     \u001b[39mreturn\u001b[39;00m draw(artist, renderer)\n\u001b[0;32m     73\u001b[0m \u001b[39mfinally\u001b[39;00m:\n\u001b[0;32m     74\u001b[0m     \u001b[39mif\u001b[39;00m artist\u001b[39m.\u001b[39mget_agg_filter() \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:1376\u001b[0m, in \u001b[0;36mAxis.draw\u001b[1;34m(self, renderer, *args, **kwargs)\u001b[0m\n\u001b[0;32m   1373\u001b[0m     \u001b[39mreturn\u001b[39;00m\n\u001b[0;32m   1374\u001b[0m renderer\u001b[39m.\u001b[39mopen_group(\u001b[39m__name__\u001b[39m, gid\u001b[39m=\u001b[39m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mget_gid())\n\u001b[1;32m-> 1376\u001b[0m ticks_to_draw \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_update_ticks()\n\u001b[0;32m   1377\u001b[0m tlb1, tlb2 \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_get_ticklabel_bboxes(ticks_to_draw, renderer)\n\u001b[0;32m   1379\u001b[0m \u001b[39mfor\u001b[39;00m tick \u001b[39min\u001b[39;00m ticks_to_draw:\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:1264\u001b[0m, in \u001b[0;36mAxis._update_ticks\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m   1262\u001b[0m major_locs \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mget_majorticklocs()\n\u001b[0;32m   1263\u001b[0m major_labels \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mmajor\u001b[39m.\u001b[39mformatter\u001b[39m.\u001b[39mformat_ticks(major_locs)\n\u001b[1;32m-> 1264\u001b[0m major_ticks \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mget_major_ticks(\u001b[39mlen\u001b[39;49m(major_locs))\n\u001b[0;32m   1265\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mmajor\u001b[39m.\u001b[39mformatter\u001b[39m.\u001b[39mset_locs(major_locs)\n\u001b[0;32m   1266\u001b[0m \u001b[39mfor\u001b[39;00m tick, loc, label \u001b[39min\u001b[39;00m \u001b[39mzip\u001b[39m(major_ticks, major_locs, major_labels):\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:1602\u001b[0m, in \u001b[0;36mAxis.get_major_ticks\u001b[1;34m(self, numticks)\u001b[0m\n\u001b[0;32m   1598\u001b[0m     numticks \u001b[39m=\u001b[39m \u001b[39mlen\u001b[39m(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mget_majorticklocs())\n\u001b[0;32m   1600\u001b[0m \u001b[39mwhile\u001b[39;00m \u001b[39mlen\u001b[39m(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mmajorTicks) \u001b[39m<\u001b[39m numticks:\n\u001b[0;32m   1601\u001b[0m     \u001b[39m# Update the new tick label properties from the old.\u001b[39;00m\n\u001b[1;32m-> 1602\u001b[0m     tick \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_get_tick(major\u001b[39m=\u001b[39;49m\u001b[39mTrue\u001b[39;49;00m)\n\u001b[0;32m   1603\u001b[0m     \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mmajorTicks\u001b[39m.\u001b[39mappend(tick)\n\u001b[0;32m   1604\u001b[0m     \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_copy_tick_props(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mmajorTicks[\u001b[39m0\u001b[39m], tick)\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:1551\u001b[0m, in \u001b[0;36mAxis._get_tick\u001b[1;34m(self, major)\u001b[0m\n\u001b[0;32m   1547\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mNotImplementedError\u001b[39;00m(\n\u001b[0;32m   1548\u001b[0m         \u001b[39mf\u001b[39m\u001b[39m\"\u001b[39m\u001b[39mThe Axis subclass \u001b[39m\u001b[39m{\u001b[39;00m\u001b[39mself\u001b[39m\u001b[39m.\u001b[39m\u001b[39m__class__\u001b[39m\u001b[39m.\u001b[39m\u001b[39m__name__\u001b[39m\u001b[39m}\u001b[39;00m\u001b[39m must define \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[0;32m   1549\u001b[0m         \u001b[39m\"\u001b[39m\u001b[39m_tick_class or reimplement _get_tick()\u001b[39m\u001b[39m\"\u001b[39m)\n\u001b[0;32m   1550\u001b[0m tick_kw \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_major_tick_kw \u001b[39mif\u001b[39;00m major \u001b[39melse\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_minor_tick_kw\n\u001b[1;32m-> 1551\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_tick_class(\u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49maxes, \u001b[39m0\u001b[39;49m, major\u001b[39m=\u001b[39;49mmajor, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mtick_kw)\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:417\u001b[0m, in \u001b[0;36mXTick.__init__\u001b[1;34m(self, *args, **kwargs)\u001b[0m\n\u001b[0;32m    416\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39m__init__\u001b[39m(\u001b[39mself\u001b[39m, \u001b[39m*\u001b[39margs, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs):\n\u001b[1;32m--> 417\u001b[0m     \u001b[39msuper\u001b[39;49m()\u001b[39m.\u001b[39;49m\u001b[39m__init__\u001b[39;49m(\u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[0;32m    418\u001b[0m     \u001b[39m# x in data coords, y in axes coords\u001b[39;00m\n\u001b[0;32m    419\u001b[0m     ax \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39maxes\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:189\u001b[0m, in \u001b[0;36mTick.__init__\u001b[1;34m(self, axes, loc, size, width, color, tickdir, pad, labelsize, labelcolor, zorder, gridOn, tick1On, tick2On, label1On, label2On, major, labelrotation, grid_color, grid_linestyle, grid_linewidth, grid_alpha, **kwargs)\u001b[0m\n\u001b[0;32m    185\u001b[0m \u001b[39mfor\u001b[39;00m artist \u001b[39min\u001b[39;00m [\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mtick1line, \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mtick2line, \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mgridline,\n\u001b[0;32m    186\u001b[0m                \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mlabel1, \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mlabel2]:\n\u001b[0;32m    187\u001b[0m     \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_set_artist_props(artist)\n\u001b[1;32m--> 189\u001b[0m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mupdate_position(loc)\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\axis.py:458\u001b[0m, in \u001b[0;36mXTick.update_position\u001b[1;34m(self, loc)\u001b[0m\n\u001b[0;32m    456\u001b[0m \u001b[39m\u001b[39m\u001b[39m\"\"\"Set the location of tick in data coords with scalar *loc*.\"\"\"\u001b[39;00m\n\u001b[0;32m    457\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mtick1line\u001b[39m.\u001b[39mset_xdata((loc,))\n\u001b[1;32m--> 458\u001b[0m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mtick2line\u001b[39m.\u001b[39;49mset_xdata((loc,))\n\u001b[0;32m    459\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mgridline\u001b[39m.\u001b[39mset_xdata((loc,))\n\u001b[0;32m    460\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mlabel1\u001b[39m.\u001b[39mset_x(loc)\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\matplotlib\\lines.py:1277\u001b[0m, in \u001b[0;36mLine2D.set_xdata\u001b[1;34m(self, x)\u001b[0m\n\u001b[0;32m   1269\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mset_xdata\u001b[39m(\u001b[39mself\u001b[39m, x):\n\u001b[0;32m   1270\u001b[0m \u001b[39m    \u001b[39m\u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m   1271\u001b[0m \u001b[39m    Set the data array for x.\u001b[39;00m\n\u001b[0;32m   1272\u001b[0m \n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1275\u001b[0m \u001b[39m    x : 1D array\u001b[39;00m\n\u001b[0;32m   1276\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[1;32m-> 1277\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39mnot\u001b[39;00m np\u001b[39m.\u001b[39;49miterable(x):\n\u001b[0;32m   1278\u001b[0m         \u001b[39m# When deprecation cycle is completed\u001b[39;00m\n\u001b[0;32m   1279\u001b[0m         \u001b[39m# raise RuntimeError('x must be a sequence')\u001b[39;00m\n\u001b[0;32m   1280\u001b[0m         _api\u001b[39m.\u001b[39mwarn_deprecated(\n\u001b[0;32m   1281\u001b[0m             since\u001b[39m=\u001b[39m\u001b[39m3.7\u001b[39m,\n\u001b[0;32m   1282\u001b[0m             message\u001b[39m=\u001b[39m\u001b[39m\"\u001b[39m\u001b[39mSetting data with a non sequence type \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[0;32m   1283\u001b[0m             \u001b[39m\"\u001b[39m\u001b[39mis deprecated since \u001b[39m\u001b[39m%(since)s\u001b[39;00m\u001b[39m and will be \u001b[39m\u001b[39m\"\u001b[39m\n\u001b[0;32m   1284\u001b[0m             \u001b[39m\"\u001b[39m\u001b[39mremove \u001b[39m\u001b[39m%(removal)s\u001b[39;00m\u001b[39m\"\u001b[39m)\n\u001b[0;32m   1285\u001b[0m         x \u001b[39m=\u001b[39m [x, ]\n",
      "File \u001b[1;32mc:\\Users\\Dell\\AppData\\Local\\Programs\\Python\\Python311\\Lib\\site-packages\\numpy\\lib\\function_base.py:346\u001b[0m, in \u001b[0;36miterable\u001b[1;34m(y)\u001b[0m\n\u001b[0;32m    342\u001b[0m         indexer \u001b[39m=\u001b[39m \u001b[39mtuple\u001b[39m(indexer)\n\u001b[0;32m    343\u001b[0m     \u001b[39mreturn\u001b[39;00m m[indexer]\n\u001b[1;32m--> 346\u001b[0m \u001b[39m@set_module\u001b[39m(\u001b[39m'\u001b[39m\u001b[39mnumpy\u001b[39m\u001b[39m'\u001b[39m)\n\u001b[0;32m    347\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39miterable\u001b[39m(y):\n\u001b[0;32m    348\u001b[0m \u001b[39m    \u001b[39m\u001b[39m\"\"\"\u001b[39;00m\n\u001b[0;32m    349\u001b[0m \u001b[39m    Check whether or not an object can be iterated over.\u001b[39;00m\n\u001b[0;32m    350\u001b[0m \n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m    382\u001b[0m \n\u001b[0;32m    383\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[0;32m    384\u001b[0m     \u001b[39mtry\u001b[39;00m:\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "# importing the required module\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# x axis values\n",
    "x = [x for x in dict1]\n",
    "# corresponding y axis values\n",
    "y = [dict1[x] for x in dict1]\n",
    "\n",
    "# plotting the points\n",
    "plt.plot(x, y)\n",
    "\n",
    "# naming the x axis\n",
    "plt.xlabel('Content')\n",
    "# naming the y axis\n",
    "plt.ylabel('Quantity')\n",
    "\n",
    "# giving a title to my graph\n",
    "plt.title('Graph')\n",
    "\n",
    "# function to show the plot\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 214,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified': [['abacavir', 3], ['abacavir/lamivudine', 6], ['abacavir/lamivudine/lopinavir/ritonavir', 1], ['atazanavir', 3], ['atazanavir/ritonavir', 1], ['cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate', 11], ['cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide', 1], ['darunavir', 8], ['didanosine', 4], ['dolutegravir', 1], ['dolutegravir/lamivudine/tenofovir', 11], ['efavirenz', 6], ['efavirenz/emtricitabine/tenofovir', 11], ['efavirenz/lamivudine/tenofovir', 11], ['efavirenz/lamivudine/tenofovir', 11], ['emtricitabine', 2], ['emtricitabine/rilpivirine/tenofovir alafenamide', 7], ['emtricitabine/rilpivirine/tenofovir disoproxil fumarate', 11], ['emtricitabine/tenofovir', 11], ['emtricitabine/tenofovir alafenamide', 7], ['indinavir', 4], ['lamivudine', 6], ['lamivudine/nevirapine/zidovudine', 3], ['lamivudine/tenofovir', 3], ['lamivudine/zidovudine', 3], ['lopinavir/ritonavir', 1], ['nelfinavir', 5], ['nevirapine', 5], ['raltegravir', 7], ['ritonavir', 1], ['saquinavir', 5], ['stavudine', 3], ['tenofovir disoproxil fumarate', 11], ['zidovudine', 3]], 'Other specified malignant neoplasms of breast': [['abemaciclib', 1], ['anastrozole', 1], ['capecitabine', 5], ['cyclophosphamide', 5], ['docetaxel', 4], ['doxorubicin', 5], ['paclitaxel', 6], ['palbociclib', 8], ['ribociclib', 6], ['tamoxifen', 2], ['vinorelbine', 8]], 'Malignant neoplasms of prostate': [['abiraterone', 5], ['bicalutamide', 5], ['docetaxel', 4], ['enzalutamide', 4], ['enzalutamide', 4], ['flutamide', 7], ['goserelin', 2], ['leuprorelin', 5], ['nilutamide', 2], ['prednisolone', 7], ['prednisone', 5], ['triptorelin', 2]], 'Primary open-angle glaucoma': [['acetazolamide', 7], ['carbachol', 7], ['epinephrine', 2], ['latanoprost', 2], ['pilocarpine', 4], ['timolol', 5]], 'Infectious diseases of external ear': [['acetic acid', 2], ['ciprofloxacin', 3], ['ofloxacin', 4]], 'Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs': [['acetylcysteine', 20], ['methionine', 7]], 'Acute or subacute hepatic failure': [['acetylcysteine', 20]], 'Migraine': [['acetylsalicylic acid', 5], ['ibuprofen', 4], ['paracetamol', 5], ['propranolol', 2], ['sumatriptan', 5]], 'Acute myocardial infarction': [['acetylsalicylic acid', 1], ['streptokinase', 3]], 'Cerebral ischaemic stroke': [['acetylsalicylic acid', 1], ['alteplase', 5]], 'Acute rheumatic fever without mention of heart involvement': [['acetylsalicylic acid', 6]], 'Mucocutaneous lymph node syndrome': [['acetylsalicylic acid', 6], ['normal immunoglobulin', 16]], 'Juvenile idiopathic arthritis': [['acetylsalicylic acid', 6], ['adalimumab', 4], ['certolizumab pegol', 12], ['etanercept', 7], ['golimumab', 2], ['infliximab', 4], ['triamcinolone acetonide', 7], ['triamcinolone hexacetonide', 2]], 'Pain': [['acetylsalicylic acid', 6], ['codeine', 3], ['hydromorphone', 1], ['ibuprofen', 6], ['morphine', 1], ['oxycodone', 7], ['paracetamol', 1]], 'Zoster': [['aciclovir', 2], ['valaciclovir', 5]], 'Varicella': [['aciclovir', 2], ['valaciclovir', 5]], 'Herpes simplex infections': [['aciclovir', 2], ['valaciclovir', 5]], 'Herpes simplex keratitis': [['aciclovir', 3], ['idoxuridine', 2]], 'Chronic obstructive pulmonary disease': [['aclidinium', 3], ['epinephrine', 1], ['glycopyrronium', 2], ['ipratropium bromide', 14], ['salbutamol', 5], ['terbutaline', 1], ['tiotropium bromide', 4], ['umeclidinium', 3]], 'Unspecified injury, poisoning or certain other consequences of external causes': [['activated charcoal', 3], ['ipecacuanha', 14]], 'Axial spondyloarthritis': [['adalimumab', 4], ['certolizumab pegol', 12], ['etanercept', 7], ['golimumab', 2], ['infliximab', 4]], 'Crohn disease site': [['adalimumab', 4], ['certolizumab pegol', 12], ['etanercept', 7], ['golimumab', 2], ['hydrocortisone', 1], ['infliximab', 4], ['mesalazine', 5], ['prednisolone', 2], ['prednisolone', 2], ['sulfasalazine', 5]], 'Rheumatoid arthritis': [['adalimumab', 4], ['certolizumab pegol', 12], ['chloroquine', 6], ['etanercept', 7], ['golimumab', 2], ['infliximab', 4]], 'Other specified malignant neoplasms of bronchus or lung': [['afatinib', 4], ['atezolizumab', 1], ['atezolizumab', 1], ['carboplatin', 6], ['cisplatin', 2], ['crizotinib', 7], ['durvalumab', 1], ['erlotinib', 6], ['etoposide', 5], ['gefitinib', 4], ['gemcitabine', 2], ['nivolumab', 1], ['nivolumab', 1], ['osimertinib', 8], ['paclitaxel', 6], ['pembrolizumab', 5], ['vinorelbine', 8]], 'Filariasis': [['albendazole', 4], ['suramin sodium', 5]], 'Echinococcosis': [['albendazole', 4]], 'Ascariasis': [['albendazole', 4], ['ivermectin', 3], ['levamisole', 6], ['mebendazole', 5], ['pyrantel', 7]], 'Enterobiasis': [['albendazole', 4], ['mebendazole', 5], ['pyrantel', 7]], 'Trichuriasis': [['albendazole', 4], ['ivermectin', 3], ['mebendazole', 5], ['pyrantel', 7]], 'Hookworm diseases': [['albendazole', 4], ['ivermectin', 3], ['mebendazole', 5], ['pyrantel', 7]], 'Cysticercosis': [['albendazole', 4]], 'Other specified echinococcosis': [['albendazole', 4], ['mebendazole', 5]], 'Cysticercosis of central nervous system': [['albendazole', 4], ['praziquantel', 5]], 'Denatured alcohol': [['alcohol based hand rub', 75], ['ethanol', 70], ['propanol', 7]], 'Muscle relaxants': [['alcuronium', 5], ['atracurium', 1], ['gallamine', 4], ['suxamethonium', 5], ['tubocurarine', 1], ['vecuronium', 1]], 'Acute myeloid leukaemia with recurrent genetic abnormalities': [['all-trans retinoic acid', 1], ['arsenic trioxide', 1], ['cytarabine', 1], ['daunorubicin', 5], ['mercaptopurine', 5], ['methotrexate', 5], ['realgar-indigo naturalis formulation', 3]], 'Gout': [['allopurinol', 1], ['colchicine', 5], ['probenecid', 5]], 'Tumour lysis syndrome': [['allopurinol', 3], ['rasburicase', 5]], 'Amidotrizoate': [['amidotrizoate', 6]], 'Neutropenia (high-risk)': [['amikacin', 7], ['imipenem/cilastatin', 5], ['meropenem', 5], ['piperacillin/tazobactam', 5], ['vancomycin', 5]], 'Acute pyelonephritis (severe)': [['amikacin', 7], ['amikacin', 7], ['cefotaxime', 7], ['ceftriaxone', 7]], 'Inflammatory and other diseases of prostate (severe)': [['amikacin', 7], ['amikacin', 7], ['cefotaxime', 7], ['ceftriaxone', 7]], 'Sepsis without septic shock': [['amikacin', 7], ['amoxicillin', 5], ['ampicillin', 5], ['benzylpenicillin', 6], ['cefotaxime', 7], ['ceftriaxone', 7], ['cloxacillin', 5], ['gentamicin', 4], ['gentamicin', 4], ['gentamicin', 4]], 'Other specified conjunctivitis': [['amikacin', 7], ['chlortetracycline', 7], ['gentamicin', 3], ['kanamycin', 3], ['netilmicin', 5], ['ofloxacin', 3], ['oxytetracycline', 7], ['sulfacetamide', 10], ['tetracycline', 1], ['tobramycin', 1]], 'Infectious blepharitis': [['amikacin', 7], ['chlortetracycline', 7], ['gentamicin', 3], ['kanamycin', 3], ['netilmicin', 5], ['oxytetracycline', 7], ['tetracycline', 1], ['tobramycin', 1]], 'Multi-drug resistant Mycobacterium tuberculosis': [['amikacin', 7], ['amoxicillin/clavulanic acid', 8], ['bedaquiline', 2], ['capreomycin', 1], ['clofazimine', 5], ['cycloserine', 8], ['delamanid', 7], ['ethionamide', 8], ['gatifloxacin', 4], ['imipenem/cilastatin', 5], ['kanamycin (injection)', 1], ['levofloxacin', 1], ['linezolid', 6], ['meropenem', 5], ['moxifloxacin', 4], ['ofloxacin', 4], ['p-aminosalicylic acid', 7], ['protionamide', 1], ['streptomycin (injection)', 3], ['terizidone', 1]], 'Oedema': [['amiloride', 5], ['bumetanide', 5], ['furosemide', 2], ['hydrochlorothiazide', 7], ['spironolactone', 7], ['torasemide', 5]], 'Ascites': [['amiloride', 5], ['spironolactone', 7]], 'Cardiac arrhythmia': [['amiodarone', 4], ['bisoprolol', 5], ['carvedilol', 6], ['digoxin', 2], ['metoprolol', 5], ['procainamide', 7], ['propranolol', 4], ['quinidine', 2]], 'Palliative care': [['amitriptyline', 12], ['cyclizine', 5], ['dexamethasone', 4], ['diazepam', 5], ['docusate sodium', 1], ['dolasetron', 1], ['fluoxetine', 2], ['granisetron', 2], ['haloperidol', 5], ['hyoscine butylbromide', 2], ['hyoscine hydrobromide', 1], ['lactulose', 5], ['loperamide', 2], ['metoclopramide', 5], ['midazolam', 5], ['ondansetron', 8], ['palonosetron', 6], ['senna', 5], ['tropisetron', 5]], 'Depressive disorders': [['amitriptyline', 12], ['citalopram', 2], ['escitalopram', 5], ['fluoxetine', 2], ['fluvoxamine', 7], ['paroxetine', 7], ['sertraline', 5]], 'Essential hypertension': [['amlodipine', 5], ['atenolol', 1], ['atenolol', 1], ['bisoprolol', 5], ['carvedilol', 6], ['chlorothiazide', 6], ['chlortalidone', 7], ['enalapril', 5], ['hydralazine', 7], ['hydrochlorothiazide', 5], ['indapamide', 5], ['lisinopril/amlodipine', 1], ['lisinopril/hydrochlorothiazide', 7], ['losartan', 1], ['methyldopa', 7], ['metoprolol', 5], ['nifedipine', 1], ['propranolol', 4], ['telmisartan/amlodipine', 1], ['telmisartan/hydrochlorothiazide', 7]], 'Malaria due to Plasmodium falciparum': [['amodiaquine', 2], ['artemether', 8], ['artemether/lumefantrine', 3], ['artesunate', 1], ['artesunate/amodiaquine', 9], ['artesunate/mefloquine', 4], ['artesunate/pyronaridine tetraphosphate', 6], ['chloroquine', 6], ['chloroquine', 1], ['dihydroartemisinin/piperaquine phosphate', 7], ['doxycycline', 1], ['doxycycline', 1], ['hydroxychloroquine', 5], ['mefloquine', 7], ['mefloquine', 7], ['proguanil', 1], ['quinine', 3], ['sulfadoxine/pyrimethamine', 7], ['sulfadoxine/pyrimethamine', 5]], 'Malaria': [['amodiaquine/sulfadoxine/pyrimethamine', 7], ['sulfadoxine/pyrimethamine', 5]], 'Acute otitis media': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8]], 'Acute pharyngitis': [['amoxicillin', 5], ['cefalexin', 5], ['clarithromycin', 5], ['erythromycin', 7], ['phenoxymethylpenicillin', 5]], 'Chronic obstructive pulmonary disease with acute exacerbation': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8], ['cefalexin', 5], ['doxycycline', 5]], 'Periapical abscess without sinus': [['amoxicillin', 5], ['phenoxymethylpenicillin', 5]], 'Acute malnutrition in infants, children or adolescents (uncomplicated) [children]': [['amoxicillin', 5]], 'Acute malnutrition in infants, children or adolescents (complicated) [children]': [['amoxicillin', 5], ['ampicillin', 5], ['benzylpenicillin', 6], ['gentamicin', 4], ['gentamicin', 4]], 'Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8], ['doxycycline', 5], ['phenoxymethylpenicillin', 5]], 'Bacterial pneumonia (Community-acquired pneumonia - severe) [children]': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8], ['ampicillin', 5], ['benzylpenicillin', 6], ['cefotaxime', 7], ['ceftriaxone', 7], ['gentamicin', 4], ['gentamicin', 4], ['gentamicin', 4]], 'Acute sinusitis': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8]], 'Bacterial meningitis': [['amoxicillin', 5], ['ampicillin', 5], ['benzylpenicillin', 6], ['cefotaxime', 7], ['ceftriaxone', 7], ['chloramphenicol', 7]], 'Bacterial infection of unspecified site': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8], ['ampicillin', 5], ['benzathine benzylpenicillin', 9], ['benzylpenicillin', 6], ['cefalexin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['chloramphenicol', 7], ['ciprofloxacin', 5], ['clindamycin', 6], ['cloxacillin', 5], ['doxycycline', 5], ['erythromycin', 7], ['gentamicin', 4], ['metronidazole', 5], ['phenoxymethylpenicillin', 5], ['spectinomycin', 5], ['sulfamethoxazole/trimethoprim', 7], ['tetracycline', 7]], 'Infectious cystitis': [['amoxicillin', 5], ['amoxicillin/clavulanic acid', 8], ['nitrofurantoin', 1], ['sulfamethoxazole/trimethoprim', 7], ['trimethoprim', 2]], 'Bacterial cellulitis, erysipelas or lymphangitis': [['amoxicillin/clavulanic acid', 8], ['cefalexin', 5], ['cloxacillin', 5]], 'Neutropenia (low-risk)': [['amoxicillin/clavulanic acid', 8], ['ciprofloxacin', 5]], 'Other specified pneumonia (Hospital-acquired pneumonia)': [['amoxicillin/clavulanic acid', 8], ['cefotaxime', 7], ['ceftriaxone', 7], ['piperacillin/tazobactam', 5]], 'Peritonitis (mild-moderate)': [['amoxicillin/clavulanic acid', 8], ['ampicillin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['ciprofloxacin', 5], ['gentamicin', 4], ['metronidazole', 5], ['metronidazole', 5], ['metronidazole', 5]], 'Peritoneal abscess (mild-moderate)': [['amoxicillin/clavulanic acid', 8], ['ampicillin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['ciprofloxacin', 5], ['gentamicin', 4], ['metronidazole', 5], ['metronidazole', 5], ['metronidazole', 5]], 'Bacterial infection of joint': [['amoxicillin/clavulanic acid', 8], ['cefazolin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['clindamycin', 6], ['cloxacillin', 5]], 'Osteomyelitis or osteitis': [['amoxicillin/clavulanic acid', 8], ['cefazolin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['clindamycin', 6], ['cloxacillin', 5]], 'Other specified prophylactic measures': [['amoxicillin/clavulanic acid', 8], ['cefazolin', 5], ['cefazolin', 5], ['cefuroxime', 12], ['gentamicin', 4], ['isoniazid/pyridoxine/sulfamethoxazole/trimethoprim', 7], ['metronidazole', 5]], 'Bacterial pneumonia (Community-acquired pneumonia - severe)': [['amoxicillin/clavulanic acid', 8], ['cefotaxime', 7], ['ceftriaxone', 7], ['clarithromycin', 5], ['clarithromycin', 5], ['clarithromycin', 5]], 'Blastomycosis': [['amphotericin B', 5]], 'Aspergillosis': [['amphotericin B', 5]], 'Cryptococcosis': [['amphotericin B', 5], ['fluconazole', 5], ['flucytosine', 7]], 'Candidosis': [['amphotericin B', 5], ['fluconazole', 5], ['nystatin', 5]], 'Coccidioidomycosis': [['amphotericin B', 5]], 'Histoplasmosis': [['amphotericin B', 5], ['itraconazole', 1]], 'Sporotrichosis': [['amphotericin B', 5], ['itraconazole', 1], ['potassium iodide', 15]], 'Visceral leishmaniasis': [['amphotericin B', 5], ['meglumine antimoniate', 1], ['miltefosine', 5], ['paromomycin', 12], ['pentamidine', 3], ['sodium stibogluconate', 1]], 'Peritonitis (severe)': [['ampicillin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['gentamicin', 4], ['imipenem/cilastatin', 5], ['meropenem', 5], ['metronidazole', 5], ['metronidazole', 5], ['piperacillin/tazobactam', 5]], 'Peritoneal abscess (severe)': [['ampicillin', 5], ['cefotaxime', 7], ['ceftriaxone', 7], ['gentamicin', 4], ['imipenem/cilastatin', 5], ['meropenem', 5], ['metronidazole', 5], ['metronidazole', 5], ['piperacillin/tazobactam', 5]], 'Juvenile systemic arthritis': [['anakinra', 1], ['tocilizumab', 9]], 'Malignant neoplasms of breast': [['anastrozole', 1], ['carboplatin', 6], ['cyclophosphamide', 5], ['docetaxel', 4], ['doxorubicin', 5], ['fluorouracil', 5], ['fulvestrant', 7], ['goserelin', 2], ['leuprorelin', 5], ['methotrexate', 5], ['paclitaxel', 6], ['tamoxifen', 2], ['triptorelin', 2]], 'Systemic or invasive candidosis': [['anidulafungin', 1], ['caspofungin', 6], ['micafungin', 1]], 'Maternal care for red cell antibodies': [['anti-d immunoglobulin', 1]], 'Rh incompatibility reaction': [['anti-d immunoglobulin', 1]], 'Rabies': [['anti-rabies immunoglobulin', 1], ['anti-rabies virus monoclonal antibodies', 1], ['antirabies hyperimmune serum', 1], ['equine rabies immunoglobulin', 1]], 'Tetanus': [['anti-tetanus immunoglobulin', 1], ['tetanus antitoxin', 2]], 'Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified': [['antivenom immunoglobulin', 1], ['antivenom sera', 1], ['dimercaprol', 5], ['fomepizole', 5], ['penicillamine', 7], ['potassium ferric hexacyanoferrate', 15], ['snake antivenom', 2], ['sodium calcium edetate', 2], ['sodium nitrite', 3], ['sodium thiosulfate', 7], ['succimer', 1]], 'Venous thromboembolism': [['apixaban', 1], ['dabigatran', 6], ['dalteparin', 4], ['edoxaban', 1], ['enoxaparin', 1], ['heparin sodium', 5], ['nadroparin', 2], ['rivaroxaban', 5], ['warfarin', 5]], 'Other specified atrial fibrillation': [['apixaban', 1], ['dabigatran', 6], ['edoxaban', 1], ['rivaroxaban', 5]], 'Nausea or vomiting': [['aprepitant', 12], ['dexamethasone', 4], ['dolasetron', 1], ['granisetron', 2], ['metoclopramide', 5], ['ondansetron', 6], ['palonosetron', 6], ['promethazine', 7], ['tropisetron', 5]], 'Malaria due to Plasmodium vivax': [['artesunate/pyronaridine tetraphosphate', 6], ['chloroquine', 6], ['chloroquine', 1], ['primaquine', 6]], 'Scurvy': [['ascorbic acid', 5]], 'Lymphoid leukaemia, not elsewhere classified': [['asparaginase', 5], ['cyclophosphamide', 5], ['cytarabine', 1], ['daunorubicin', 5], ['dexamethasone', 4], ['doxorubicin', 5], ['etoposide', 5], ['hydrocortisone', 1], ['mercaptopurine', 5], ['methotrexate', 5], ['methylprednisolone', 8], ['pegaspargase', 7], ['prednisolone', 7], ['prednisone', 5], ['tioguanine', 4], ['vincristine', 2]], 'Unspecified malignant neoplasms of ill-defined or unspecified sites': [['asparaginase', 5], ['bleomycin', 6], ['calcium folinate', 6], ['chlorambucil', 2], ['cisplatin', 2], ['cyclophosphamide', 5], ['cytarabine', 1], ['dactinomycin', 4], ['docetaxel', 4], ['doxorubicin', 5], ['etoposide', 5], ['fluorouracil', 5], ['hydrocortisone', 1], ['ifosfamide', 5], ['mercaptopurine', 5], ['mesna', 6], ['methotrexate', 5], ['prednisolone', 7], ['procarbazine', 5], ['vinblastine', 1], ['vincristine', 2]], 'Angina pectoris': [['atenolol', 1], ['bisoprolol', 5], ['carvedilol', 6], ['glyceryl trinitrate', 2], ['isosorbide dinitrate', 5], ['metoprolol', 5], ['nifedipine', 1], ['propranolol', 4], ['verapamil', 8]], 'Mixed hyperlipidaemia': [['atorvastatin', 1], ['fluvastatin', 7], ['lovastatin', 1], ['pravastatin', 12], ['simvastatin', 4]], 'Coronary atherosclerosis': [['atorvastatin', 1], ['fluvastatin', 7], ['lovastatin', 1], ['pravastatin', 12], ['simvastatin', 4]], 'Exposure to or harmful effects of undetermined intent of pesticides': [['atropine', 1], ['pralidoxime', 1]], 'Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics': [['atropine', 1]], 'Cycloplegic drug': [['atropine', 1], ['cyclopentolate', 5], ['tropicamide', 5]], 'Anterior uveitis': [['atropine', 1], ['cyclopentolate', 5], ['homatropine', 2], ['homatropine', 2], ['hydrocortisone', 1], ['prednisolone', 5]], 'Myeloid leukaemia': [['azacitidine', 1], ['cytarabine', 1], ['daunorubicin', 5], ['etoposide', 5]], 'Rheumatoid arthritis, serology unspecified': [['azathioprine', 5], ['methotrexate', 5], ['penicillamine', 7], ['sulfasalazine', 5]], 'Psoriatic arthritis': [['azathioprine', 5]], 'Failure or rejection of transplanted organs or tissues': [['azathioprine', 5], ['ciclosporin', 7], ['tacrolimus', 5]], 'Relapsing-remitting multiple sclerosis': [['azathioprine', 5], ['fingolimod', 5], ['glatiramer acetate', 4], ['ocrelizumab', 3]], 'Chlamydia trachomatis': [['azithromycin', 5], ['doxycycline', 5]], 'Paratyphoid fever': [['azithromycin', 5], ['ceftriaxone', 7], ['ciprofloxacin', 5]], 'Typhoid fever': [['azithromycin', 5], ['ceftriaxone', 7], ['ciprofloxacin', 5]], 'Gonococcal infection': [['azithromycin', 5], ['azithromycin', 5], ['cefixime', 4], ['ceftriaxone', 7], ['gentamicin', 4], ['spectinomycin', 5]], 'Trachoma': [['azithromycin', 5], ['azithromycin', 5], ['chlortetracycline', 7], ['oxytetracycline', 7], ['tetracycline', 1]], 'Yaws': [['azithromycin', 5]], 'Cholera': [['azithromycin', 5], ['ciprofloxacin', 5], ['doxycycline', 5]], 'Cholera [children]': [['azithromycin', 5], ['ciprofloxacin', 5], ['doxycycline', 5]], 'Infectious gastroenteritis or colitis without specification of infectious agent': [['azithromycin', 5], ['cefixime', 4], ['ceftriaxone', 7], ['ciprofloxacin', 5], ['sulfamethoxazole/trimethoprim', 7]], 'Other specified bacterial diseases': [['aztreonam', 5], ['cefepime', 5], ['ceftaroline', 6], ['colistin (injection)', 5], ['daptomycin', 5], ['fifth generation cephalosporins', 6], ['fosfomycin (injection)', 5], ['fourth generation cephalosporins', 5], ['linezolid', 6], ['oxazolindinones', 7], ['polymyxins', 5], ['tigecycline', 5]], 'Barium sulfate with suspending agents': [['barium sulfate', 5]], 'Need for immunization against tuberculosis': [['bcg vaccine', 5]], 'Asthma': [['beclometasone', 5], ['beclometasone', 5], ['beclometasone/formoterol', 5], ['budesonide', 5], ['budesonide/formoterol', 5], ['budesonide/salmeterol', 5], ['ciclesonide', 7], ['epinephrine', 1], ['flunisolide', 1], ['fluticasone', 7], ['fluticasone/formoterol', 7], ['fluticasone furoate/vilanterol', 7], ['ipratropium bromide', 14], ['mometasone', 5], ['mometasone/formoterol', 5], ['salbutamol', 5], ['terbutaline', 1]], 'Chronic lymphocytic leukaemia or small lymphocytic lymphoma': [['bendamustine', 9], ['chlorambucil', 2], ['cyclophosphamide', 5], ['fludarabine', 1], ['ibrutinib', 5], ['prednisolone', 7], ['prednisone', 5], ['rituximab', 5], ['zanubrutinib', 8]], 'Follicular lymphoma': [['bendamustine', 9], ['cyclophosphamide', 5], ['doxorubicin', 5], ['prednisolone', 7], ['prednisone', 5], ['rituximab', 5], ['vincristine', 2]], 'Congenital syphilis [children]': [['benzathine benzylpenicillin', 9], ['benzylpenicillin', 6], ['procaine benzylpenicillin', 7]], 'Syphilis': [['benzathine benzylpenicillin', 9], ['benzylpenicillin', 6], ['procaine benzylpenicillin', 7]], 'Chagas disease': [['benznidazole', 5], ['nifurtimox', 7]], 'Fungal infection of the skin': [['benzoic acid/salicylic acid', 3], ['miconazole', 2], ['terbinafine', 1]], 'Acne': [['benzoyl peroxide', 5]], 'Pthiriasis': [['benzyl benzoate', 25], ['precipitated sulfur', 5]], 'Pediculosis corporis': [['benzyl benzoate', 25], ['permethrin', 5], ['precipitated sulfur', 5]], 'Pediculosis capitis': [['benzyl benzoate', 25], ['permethrin', 5], ['precipitated sulfur', 5]], 'Scabies': [['benzyl benzoate', 25], ['ivermectin', 3], ['lindane', 1], ['permethrin', 5], ['precipitated sulfur', 5]], 'Pruritus due to skin disorder': [['betamethasone', 1], ['hydrocortisone', 1]], 'Psoriasis of unspecified type': [['betamethasone', 1], ['calcipotriol', 5], ['calcitriol', 5], ['coal tar', 5], ['hydrocortisone', 1], ['salicylic acid', 5], ['tacalcitol', 5]], 'Dermatitis or eczema': [['betamethasone', 1], ['hydrocortisone', 1]], 'Lichen planus': [['betamethasone', 1], ['hydrocortisone', 1]], 'Age related macular degeneration': [['bevacizumab', 7], ['ranibizumab', 7]], 'Other specified melanoma of skin': [['binimetinib', 5], ['cobimetinib', 1], ['dabrafenib', 12], ['encorafenib', 5], ['trametinib', 2], ['vemurafenib', 1]], 'Parkinson disease': [['biperiden', 2], ['bromocriptine', 5], ['cabergoline', 5], ['dihydroergocryptine mesylate', 7], ['levodopa', 7], ['levodopa/benserazide', 7], ['levodopa/carbidopa', 7], ['pramipexole', 12], ['ropinirole', 3], ['trihexyphenidyl', 5], ['trihexyphenidyl', 5]], 'Constipation': [['bisacodyl', 2], ['senna', 5]], 'Heart failure': [['bisoprolol', 5], ['bumetanide', 5], ['captopril', 7], ['carvedilol', 6], ['chlorothiazide', 6], ['chlortalidone', 7], ['digitoxin', 2], ['digoxin', 2], ['dopamine', 4], ['enalapril', 5], ['furosemide', 4], ['hydrochlorothiazide', 7], ['indapamide', 5], ['losartan', 1], ['metoprolol', 5], ['spironolactone', 7], ['torasemide', 5]], 'Germ cell tumour of testis': [['bleomycin', 6], ['carboplatin', 6], ['cisplatin', 2], ['etoposide', 5], ['ifosfamide', 5], ['mesna', 6], ['vinblastine', 1]], 'Hodgkin lymphoma': [['bleomycin', 6], ['cyclophosphamide', 5], ['dacarbazine', 1], ['doxorubicin', 5], ['etoposide', 5], ['prednisolone', 7], ['prednisone', 5], ['procarbazine', 5], ['tislelizumab', 1], ['vinblastine', 1], ['vincristine', 2]], 'Other specified malignant neoplasms of the ovary': [['bleomycin', 6], ['carboplatin', 6], ['cisplatin', 2], ['etoposide', 5], ['ifosfamide', 5], ['mesna', 6], ['paclitaxel', 6], ['vinblastine', 1]], 'Kaposi sarcoma of unspecified primary site': [['bleomycin', 6], ['doxorubicin', 5], ['paclitaxel', 6], ['vinblastine', 1], ['vincristine', 2]], 'Plasma cell myeloma': [['bortezomib', 5], ['cyclophosphamide', 5], ['daratumumab', 4], ['dexamethasone', 4], ['doxorubicin', 5], ['lenalidomide', 7], ['melphalan', 2], ['prednisolone', 7], ['prednisone', 5], ['thalidomide', 5]], 'Allergic rhinitis': [['budesonide', 5]], 'Anuria or oliguria': [['bumetanide', 5], ['furosemide', 2], ['torasemide', 5]], 'Local anaesthetics': [['bupivacaine', 5], ['lidocaine', 4], ['lidocaine/epinephrine', 2], ['tetracaine', 5]], 'Opioid dependence': [['buprenorphine', 5], ['methadone', 1]], 'Nicotine dependence': [['bupropion', 6], ['nicotine replacement therapy', 3], ['varenicline', 1]], 'Hereditary angioedema': [['c1 esterase inhibitor', 6]], 'Apnoea of newborn': [['caffeine citrate', 1]], 'Pruritus': [['calamine', 1]], 'Calcium deficiency': [['calcium', 5], ['colecalciferol', 5], ['colecalciferol', 5], ['ergocalciferol', 7], ['ergocalciferol', 7]], 'Malignant neoplasm metastasis in large intestine': [['calcium folinate', 6], ['capecitabine', 5], ['fluorouracil', 5], ['irinotecan', 5], ['oxaliplatin', 2]], 'Burkitt lymphoma including Burkitt leukaemia': [['calcium folinate', 6], ['cyclophosphamide', 5], ['cytarabine', 1], ['dexamethasone', 4], ['doxorubicin', 5], ['etoposide', 5], ['hydrocortisone', 1], ['ifosfamide', 5], ['mesna', 6], ['methotrexate', 5], ['methylprednisolone', 8], ['prednisolone', 7], ['prednisone', 5], ['vincristine', 2]], 'Osteosarcoma of bone and articular cartilage of unspecified sites': [['calcium folinate', 6], ['carboplatin', 6], ['cisplatin', 2], ['doxorubicin', 5], ['etoposide', 5], ['ifosfamide', 5], ['methotrexate', 5]], 'Malignant neoplasms of rectum': [['calcium folinate', 6], ['capecitabine', 5], ['fluorouracil', 5]], 'Malignant neoplasms of colon': [['calcium folinate', 6], ['capecitabine', 5], ['fluorouracil', 5], ['oxaliplatin', 2]], 'Malignant trophoblastic neoplasms of placenta': [['calcium folinate', 6], ['cyclophosphamide', 5], ['dactinomycin', 4], ['etoposide', 5], ['methotrexate', 5], ['vincristine', 2]], 'Hypermagnesaemia': [['calcium gluconate', 1]], 'Tetany due to acute calcium deficiency': [['calcium gluconate', 1]], 'Type 2 diabetes mellitus': [['canagliflozin', 1], ['dapagliflozin', 4], ['empagliflozin', 7], ['glibenclamide', 5], ['gliclazide', 8], ['insulin', 4], ['insulin analogues', 4], ['insulin degludec', 4], ['insulin detemir', 4], ['insulin glargine', 4], ['intermediate-acting insulin', 4], ['long-acting insulin analogues', 3], ['metformin', 5], ['tolbutamide', 5]], 'Acute angle closure with pupillary block': [['carbachol', 7], ['pilocarpine', 4]], 'Ocular hypertension': [['carbachol', 7], ['mannitol', 20], ['pilocarpine', 4], ['timolol', 5]], 'Epilepsy or seizures': [['carbamazepine', 2], ['lamotrigine', 2], ['phenobarbital', 2], ['phenytoin', 5], ['valproic acid (sodium valproate)', 1]], 'Bipolar or related disorders': [['carbamazepine', 2], ['lithium carbonate', 3], ['valproic acid (sodium valproate)', 5]], 'Postpartum haemorrhage': [['carbetocin', 2], ['ergometrine', 7], ['methylergometrine', 7], ['misoprostol', 5], ['oxytocin', 7], ['tranexamic acid', 1]], 'Thyrotoxicosis': [['carbimazole', 2], [\"lugol's solution\", 4], ['methimazole', 2], ['potassium iodide', 6], ['propylthiouracil', 5]], 'Other specified gliomas of brain': [['carboplatin', 6], ['cisplatin', 2], ['cyclophosphamide', 5], ['everolimus', 5], ['vinblastine', 1], ['vincristine', 2]], 'Other specified carcinomas of ovary': [['carboplatin', 6], ['gemcitabine', 2], ['paclitaxel', 6]], 'Retinoblastoma': [['carboplatin', 6], ['etoposide', 5], ['vincristine', 2]], 'Malignant neoplasms of nasopharynx': [['carboplatin', 6], ['cisplatin', 2], ['fluorouracil', 5], ['paclitaxel', 6]], 'Malignant neoplasms of kidney, except renal pelvis': [['carboplatin', 6], ['cyclophosphamide', 5], ['dactinomycin', 4], ['doxorubicin', 5], ['etoposide', 5], ['ifosfamide', 5], ['irinotecan', 5], ['mesna', 6], ['vincristine', 2]], 'Malignant neoplasms of lip, oral cavity or pharynx': [['carboplatin', 6], ['cisplatin', 2]], 'Malignant neoplasms of cervix uteri': [['carboplatin', 6], ['cisplatin', 2], ['paclitaxel', 6]], 'Surgical site infection': [['cefazolin', 5]], 'Carbapenem-resistant Pseudomonas aeruginosa': [['cefiderocol', 5], ['ceftazidime/avibactam', 7], ['ceftolozane/tazobactam', 7], ['colistin (injection)', 5], ['fosfomycin (injection)', 5], ['meropenem/vaborbactam', 5], ['plazomicin', 5], ['polymyxin B (injection)', 5]], 'Carbapenem resistant Enterobacterales': [['cefiderocol', 5], ['ceftazidime/avibactam', 7], ['colistin (injection)', 5], ['eravacycline', 5], ['fosfomycin (injection)', 5], ['meropenem/vaborbactam', 5], ['plazomicin', 5], ['polymyxin B (injection)', 5]], 'Inflammatory and other diseases of prostate (mild to moderate)': [['cefotaxime', 7], ['ceftriaxone', 7], ['ciprofloxacin', 5]], 'Acute pyelonephritis (mild to moderate)': [['cefotaxime', 7], ['ceftriaxone', 7], ['ciprofloxacin', 5]], 'Endophthalmitis': [['ceftazidime', 7], ['ceftriaxone', 7], ['vancomycin', 5], ['vancomycin', 5]], 'Pseudomonas aeruginosa resistant to other antibiotic': [['ceftazidime', 7], ['imipenem/cilastatin', 5]], 'Necrotising fasciitis': [['ceftriaxone', 7], ['clindamycin', 6], ['metronidazole', 5], ['piperacillin/tazobactam', 5], ['vancomycin', 5]], 'Allergic or hypersensitivity conditions of unspecified type': [['cetirizine', 12], ['dexamethasone', 4], ['fexofenadine', 6], ['loratadine', 1], ['prednisolone', 7], ['prednisone', 5]], 'Omphalitis of newborn': [['chlorhexidine', 4]], 'Chlorhexidine': [['chlorhexidine', 5]], 'Disinfectant, not elsewhere classified': [['chlorine base compound', 1], ['hypochlorous acid', 1]], 'Malaria due to Plasmodium ovale': [['chloroquine', 6], ['primaquine', 6]], 'Malaria due to Plasmodium malariae': [['chloroquine', 6]], 'Phenol disinfectant, not elsewhere classified': [['chloroxylenol', 8]], 'Schizophrenia or other primary psychotic disorders': [['chlorpromazine', 7], ['clozapine', 2], ['fluphenazine', 7], ['haloperidol', 5], ['paliperidone', 6], ['risperidone', 6], ['risperidone', 6]], 'Infectious keratitis': [['chlortetracycline', 7], ['natamycin', 5], ['ofloxacin', 3], ['oxytetracycline', 7], ['tetracycline', 1]], 'Need for immunization against cholera alone': [['cholera vaccine', 7]], 'Gastro-oesophageal reflux disease': [['cimetidine', 2], ['omeprazole', 4], ['ranitidine', 7]], 'Peptic ulcer, site unspecified': [['cimetidine', 2], ['omeprazole', 4], ['ranitidine', 7]], 'Helicobacter pylori associated gastric ulcer': [['clarithromycin', 5]], 'Leprosy': [['clofazimine', 5], ['dapsone', 7], ['rifampicin', 3]], 'Female infertility without specification whether primary or secondary': [['clomifene', 5]], 'Obsessive-compulsive disorder': [['clomipramine', 7]], 'Generalised myoclonic seizure': [['clonazepam', 7]], 'Acute ischaemic heart disease': [['clopidogrel', 3], ['dalteparin', 4], ['enoxaparin', 1], ['heparin sodium', 5], ['nadroparin', 2]], 'Presence of coronary angioplasty implant or graft': [['clopidogrel', 3]], 'Vulvovaginal candidosis': [['clotrimazole', 5]], 'Coagulation defects, purpura or other haemorrhagic or related conditions': [['coagulation factor IX complex', 2]], 'Haemophilia B': [['coagulation factor IX complex', 2]], 'Haemophilia A': [['coagulation factor VIII', 2], ['desmopressin', 7]], 'Cough': [['codeine', 1]], 'Diarrhoea': [['codeine', 3], ['oral rehydration salts', 6], ['oral rehydration salts - zinc sulfate', 2], ['zinc sulfate', 2]], 'Vitamin D deficiency': [['colecalciferol', 5], ['colecalciferol', 5], ['ergocalciferol', 7], ['ergocalciferol', 7]], 'Carbapenem resistant Acinetobacter baumannii': [['colistin (injection)', 5], ['meropenem/vaborbactam', 5], ['plazomicin', 5], ['polymyxin B (injection)', 5]], 'Other specified disorders of fluid, electrolyte or acid-base balance': [['compound sodium lactate solution', 5], ['glucose', 50], ['glucose/sodium chloride', 45], ['oral rehydration salts', 6], ['sodium chloride', 9]], 'Hypovolaemic shock': [['compound sodium lactate solution', 5]], 'Contact with health services for contraceptive management': [['condoms', 5], ['diaphragms', 6], ['ethinylestradiol/etonogestrel', 7], ['ethinylestradiol/levonorgestrel', 7], ['ethinylestradiol/norethisterone', 1], ['levonorgestrel', 5], ['norethisterone', 1], ['progesterone vaginal ring', 5]], 'Contact with health services for insertion of contraceptive device': [['copper-containing intrauterine device', 5], ['etonogestrel-releasing implant', 14], ['levonorgestrel', 7], ['levonorgestrel-releasing implant', 12]], 'Anaemias or other erythrocyte disorders': [['cyanocobalamin', 7]], 'Diffuse large B-cell lymphomas': [['cyclophosphamide', 5], ['doxorubicin', 5], ['prednisolone', 7], ['prednisone', 5], ['rituximab', 5], ['vincristine', 2]], 'Ewing sarcoma of bone and articular cartilage of unspecified sites': [['cyclophosphamide', 5], ['dactinomycin', 4], ['doxorubicin', 5], ['etoposide', 5], ['ifosfamide', 5], ['mesna', 6], ['vincristine', 2]], 'Rhabdomyosarcoma primary site': [['cyclophosphamide', 5], ['dactinomycin', 4], ['doxorubicin', 5], ['ifosfamide', 5], ['irinotecan', 5], ['mesna', 6], ['vincristine', 2], ['vinorelbine', 8]], 'Chronic hepatitis C': [['daclatasvir', 6], ['daclatasvir/sofosbuvir', 4], ['dasabuvir', 7], ['elbasvir/grazoprevir', 1], ['glecaprevir/pibrentasvir', 2], ['ledipasvir/sofosbuvir', 4], ['ombitasvir/paritaprevir/ritonavir', 5], ['pegylated interferon alfa (2a)', 7], ['pegylated interferon alfa (2b)', 7], ['ribavirin', 6], ['simeprevir', 6], ['sofosbuvir', 2], ['sofosbuvir/velpatasvir', 5]], 'Anaemia due to chronic disease': [['darbepoetin alfa', 4], ['epoetin alfa', 1], ['epoetin beta', 1], ['epoetin theta', 1], ['erythropoiesis-stimulating agents', 5], ['methoxy polyethylene glycol-epoetin beta', 5]], 'Chronic myeloid leukaemia, not elsewhere classified': [['dasatinib', 5], ['hydroxycarbamide', 5], ['imatinib', 4], ['nilotinib', 2]], 'Other specified sickle cell disorders or other haemoglobinopathies': [['deferasirox', 5], ['deferoxamine', 5], ['hydroxycarbamide', 5]], 'Harmful effects of drugs, medicaments or biological substances, not elsewhere classified': [['deferoxamine', 5]], 'Methicillin resistant Staphylococcus aureus': [['delafloxacin', 9], ['linezolid', 6], ['omadacycline', 3], ['vancomycin', 5]], 'Need for immunization against certain single viral diseases': [['dengue vaccine', 7], ['hpv vaccine', 2], ['japanese encephalitis vaccine', 3], ['rotavirus vaccine', 3], ['smallpox vaccine', 2], ['varicella vaccine', 1], ['yellow fever vaccine', 5]], 'Von Willebrand disease': [['desmopressin', 7]], 'Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy': [['dexamethasone', 4]], 'Hypovolaemia': [['dextran 40', 4], ['dextran 70', 6], ['polygeline', 5], ['polygeline', 5]], 'Status epilepticus': [['diazepam', 5], ['diazepam', 5], ['lorazepam', 4], ['midazolam', 1], ['midazolam', 1], ['phenobarbital', 2], ['valproic acid (sodium valproate)', 1]], 'Anxiety': [['diazepam', 2]], 'Persistent hyperinsulinaemic hypoglycaemia of infancy': [['diazoxide', 5]], 'Lymphatic filariasis': [['diethylcarbamazine', 1], ['ivermectin', 3]], 'Amoebiasis': [['diloxanide', 5], ['metronidazole', 5], ['paromomycin', 7], ['tinidazole', 5]], 'Need for immunization against diphtheria alone': [['diphtheria antitoxin', 5], ['diphtheria vaccine', 5]], 'Need for immunization against diphtheria-tetanus-pertussis, combined': [['diphtheria-pertussis-tetanus vaccine', 5]], 'Need for immunization against combinations of infectious diseases': [['diphtheria-tetanus vaccine', 5]], 'Cardiogenic shock': [['dopamine', 4], ['isoprenaline', 6]], 'African trypanosomiasis': [['eflornithine', 2], ['fexinidazole', 6], ['fexinidazole', 6], ['melarsoprol', 9], ['nifurtimox', 3], ['pentamidine', 2], ['suramin sodium', 5]], 'Contact with or exposure to human immunodeficiency virus': [['emtricitabine/tenofovir', 11], ['lamivudine/tenofovir', 3], ['tenofovir disoproxil fumarate', 11]], 'Chronic hepatitis B': [['entecavir', 1], ['tenofovir alafenamide', 7], ['tenofovir disoproxil fumarate', 11]], 'Cardiac complications of anaesthesia during labour or delivery': [['ephedrine', 3]], 'Cardiac arrest': [['epinephrine', 3]], 'Anaphylaxis': [['epinephrine', 1], ['hydrocortisone', 1]], 'Gonococcal infection of eye': [['erythromycin', 5]], 'Chlamydial conjunctivitis': [['erythromycin', 5]], 'Contact with health services for reasons associated with reproduction': [['estradiol cypionate/medroxyprogesterone acetate', 7], ['medroxyprogesterone acetate', 5], ['norethisterone enantate', 2]], 'Tuberculosis': [['ethambutol', 2], ['ethambutol/isoniazid', 6], ['ethambutol/isoniazid/pyrazinamide/rifampicin', 6], ['ethambutol/isoniazid/rifampicin', 6], ['isoniazid', 1], ['isoniazid/pyrazinamide/rifampicin', 12], ['isoniazid/rifampicin', 3], ['moxifloxacin', 4], ['pyrazinamide', 5], ['rifabutin', 6], ['rifampicin', 6], ['rifapentine', 3]], 'Other specified tuberculosis': [['ethambutol', 2], ['isoniazid', 1], ['rifampicin', 6]], 'Anaesthetics and therapeutic gases': [['ether', 70], ['halothane', 5], ['isoflurane', 5], ['ketamine', 5], ['nitrous oxide', 1], ['oxygen', 7], ['propofol', 2], ['thiopental', 5]], 'Contact with health services for postcoital contraception': [['ethinylestradiol/levonorgestrel', 7], ['levonorgestrel', 5], ['ulipristal', 3]], 'Absence seizures, typical': [['ethosuximide', 7]], 'Chronic cancer pain': [['fentanyl', 5], ['methadone', 1], ['tramadol', 5]], 'Iron deficiency anaemia': [['ferrous salt', 6], ['ferrous salt/folic acid', 8], ['multiple micronutrient powder', 4]], 'Maternal care for other specified conditions predominantly related to pregnancy': [['ferrous salt/folic acid', 8], ['multiple micronutrient supplement', 2]], 'Acquired neutropaenia': [['filgrastim', 6]], 'Adrenocortical insufficiency': [['fludrocortisone', 1], ['hydrocortisone', 2]], 'Fluorescein': [['fluorescein', 1]], 'Dental caries': [['fluoride', 1], ['glass ionomer cement', 3], ['silver diamine fluoride', 38]], 'Plantar warts': [['fluorouracil', 5], ['podophyllotoxin', 5], ['podophyllum resin', 25]], 'Folate deficiency anaemia': [['folic acid', 5]], 'Cephalocele': [['folic acid', 5]], 'Anencephaly or similar anomalies': [['folic acid', 5]], 'Spina bifida': [['folic acid', 5]], 'Blood transfusion without reported diagnosis': [['fresh-frozen plasma', 5], ['platelets', 5], ['red blood cells', 3], ['whole blood', 5]], 'Neuropathic pain': [['gabapentin', 8]], 'Neonatal meningitis': [['gentamicin', 4], ['meropenem', 5]], 'Hypoglycaemia in the context of diabetes': [['glucagon', 1]], 'Hypoglycaemia without associated diabetes': [['glucose', 50]], 'Glutaral nonmedicinal': [['glutaral', 2]], 'Dermatophytosis': [['griseofulvin', 7]], 'Need for immunization against single bacterial diseases': [['haemophilus influenzae type b vaccine', 7], ['meningococcal meningitis vaccine', 2], ['pneumococcal vaccine', 5]], 'Unstable angina': [['heparin sodium', 5]], 'Need for immunization against viral hepatitis': [['hepatitis a vaccine', 5], ['hepatitis b vaccine', 5]], 'Gestational hypertension': [['hydralazine', 7], ['methyldopa', 7]], 'Scleritis': [['hydrocortisone', 1], ['prednisolone', 5]], 'Ulcerative colitis': [['hydrocortisone', 1], ['mesalazine', 5], ['prednisolone', 2], ['sulfasalazine', 5]], 'Megaloblastic anaemia due to vitamin B12 deficiency': [['hydroxocobalamin', 1]], 'Squamous cell carcinoma of oropharynx': [['hydroxycarbamide', 5]], 'Systemic lupus erythematosus': [['hydroxychloroquine', 2]], 'Cutaneous lupus erythematosus of unspecified type': [['hydroxychloroquine', 2]], 'Patent arterial duct': [['ibuprofen', 5], ['indometacin', 4]], 'B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1': [['imatinib', 4]], 'Gastrointestinal stromal tumour of unspecified gastrointestinal sites': [['imatinib', 4]], 'Antibiotic resistant Acinetobacter baumannii': [['imipenem/cilastatin', 5]], 'Need for immunization against influenza': [['influenza vaccine (seasonal)', 4]], 'Type 1 diabetes mellitus': [['insulin', 4], ['insulin analogues', 4], ['insulin degludec', 4], ['insulin degludec', 4], ['insulin detemir', 4], ['insulin detemir', 4], ['insulin glargine', 4], ['insulin glargine', 4], ['intermediate-acting insulin', 4], ['long-acting insulin analogues', 3]], 'Care involving peritoneal dialysis': [['intraperitoneal dialysis solution', 4]], 'Iodine deficiency': [['iodine', 10]], 'Povidone iodine': [['iodine', 10], ['povidone iodine', 1]], 'X-ray contrast media, iodinated': [['iohexol', 8], ['meglumine iotroxate', 1]], 'Latent tuberculosis': [['isoniazid/rifapentine', 3], ['rifapentine', 3]], 'Bradycardia': [['isoprenaline', 6]], 'Chronic pulmonary aspergillosis': [['itraconazole', 1], ['voriconazole', 2]], 'Chromoblastomycosis': [['itraconazole', 1]], 'Talaromycosis': [['itraconazole', 1]], 'Paracoccidioidomycosis': [['itraconazole', 1]], 'Strongyloidiasis': [['ivermectin', 3]], 'Ancylostomiasis': [['ivermectin', 3]], 'Onchocerciasis': [['ivermectin', 3]], 'Hypothyroidism': [['levothyroxine', 12]], 'Ventricular tachyarrhythmia': [['lidocaine', 2]], 'Vancomycin resistant Staphylococcus aureus': [['linezolid', 6]], 'Vancomycin resistant Enterococcus': [['linezolid', 6]], 'Severe pre-eclampsia': [['magnesium sulfate', 50]], 'Eclampsia': [['magnesium sulfate', 50]], 'Cerebral oedema': [['mannitol', 20]], 'Need for immunization against measles alone': [['measles vaccine', 20]], 'Excessive menstruation with irregular cycle': [['medroxyprogesterone acetate', 5], ['norethisterone', 5], ['norethisterone', 5]], 'Mucocutaneous leishmaniasis': [['meglumine antimoniate', 1], ['miltefosine', 5], ['sodium stibogluconate', 1]], 'Cutaneous leishmaniasis': [['meglumine antimoniate', 1], ['miltefosine', 5], ['sodium stibogluconate', 1]], 'Osteosarcoma of bone and articular cartilage of other specified sites': [['mesna', 6]], 'Attention deficit hyperactivity disorder': [['methylphenidate', 7]], 'Acquired methaemoglobinaemia': [['methylthioninium chloride', 1]], 'Trichomoniasis': [['metronidazole', 5]], 'Intestinal infections due to Clostridioides difficile': [['metronidazole', 5], ['vancomycin', 5]], 'Sedative-hypnotic and anxiolytic drugs': [['midazolam', 5]], 'Induced abortion': [['mifepristone - misoprostol', 2]], 'Spontaneous abortion, incomplete, without complication': [['misoprostol', 5]], 'Unspecified obstetric condition': [['misoprostol', 5]], 'Opioids or related analgesics\\xa0and agents affecting opioid receptors': [['morphine', 1]], 'Need for immunization against mumps alone': [['mumps vaccine', 2]], 'Superficial bacterial folliculitis': [['mupirocin', 2]], 'Impetigo': [['mupirocin', 2], ['potassium permanganate', 6]], 'Shigella resistant to unspecified antibiotic': [['nalidixic acid', 5]], 'Unintentional exposure to or harmful effects of opioids or related analgesics': [['naloxone', 5]], 'Myasthenia gravis': [['neostigmine', 5], ['pyridostigmine', 6]], 'Anticholinesterase reversible': [['neostigmine', 5]], 'Hymenolepiasis': [['niclosamide', 5], ['praziquantel', 6]], 'Diphyllobothriasis': [['niclosamide', 5], ['praziquantel', 6]], 'Taeniasis due to Taenia saginata': [['niclosamide', 5], ['praziquantel', 6]], 'Taeniasis due to Taenia solium': [['niclosamide', 5], ['praziquantel', 6]], 'Pellagra': [['nicotinamide', 5]], 'Preterm labour without delivery': [['nifedipine', 1]], 'Melanoma of skin': [['nivolumab', 1], ['pembrolizumab', 5]], 'Primary immunodeficiencies': [['normal immunoglobulin', 16]], 'Gastrointestinal bleeding': [['omeprazole', 4]], 'Influenza due to identified seasonal influenza virus': [['oseltamivir', 12]], 'Schistosomiasis due to Schistosoma mansoni': [['oxamniquine', 7]], 'Respiratory failure as acute or chronic': [['oxygen', 7]], 'Enzyme intestinal': [['pancreatic enzymes', 6]], 'Pneumocystosis': [['pentamidine', 3], ['sulfamethoxazole/trimethoprim', 7]], 'Need for immunization against pertussis alone': [['pertussis vaccine', 5]], 'Carcinoma of breast, specialised type': [['pertuzumab', 6], ['trastuzumab', 8], ['trastuzumab emtansine', 7]], 'Haemorrhagic disorder due to other specified circulating anticoagulants': [['phytomenadione', 1], ['protamine sulfate', 1]], 'Haemorrhagic or haematological disorders of fetus or newborn': [['phytomenadione', 1]], 'Anogenital warts': [['podophyllotoxin', 5], ['podophyllum resin', 25]], 'Need for immunization against poliomyelitis': [['poliomyelitis vaccine', 25]], 'Hypokalaemia': [['potassium chloride', 5], ['potassium chloride', 15]], 'Tropical phagedaenic ulcer': [['potassium permanganate', 6]], 'Pemphigus': [['potassium permanganate', 6]], 'Other specified pyogenic bacterial infection of skin and subcutaneous tissue': [['potassium permanganate', 6]], 'Paragonimiasis': [['praziquantel', 6], ['triclabendazole', 7]], 'Clonorchiasis': [['praziquantel', 6]], 'Opisthorchiasis': [['praziquantel', 6]], 'Schistosomiasis': [['praziquantel', 6]], 'Other specified congenital anomaly of great arteries including arterial duct': [['prostaglandin E1', 5], ['prostaglandin E2', 1], ['prostaglandin E2', 1]], 'Other specified polyneuropathy': [['pyridoxine', 7]], 'Vitamin B6 deficiency': [['pyridoxine', 7]], 'Sideroblastic anaemia': [['pyridoxine', 7]], 'Toxoplasmosis': [['pyrimethamine', 7], ['sulfadiazine', 5]], 'Need for immunization against rabies': [['rabies vaccine', 3]], 'Retinal venous occlusions': [['ranibizumab', 7]], 'Diabetic macular oedema': [['ranibizumab', 7]], 'Degenerative high myopia': [['ranibizumab', 7]], 'Acute malnutrition in infants, children or adolescents': [['ready to use therapeutic food', 5]], 'Vitamin A deficiency': [['retinol', 3]], 'Viral haemorrhagic fever, not elsewhere classified': [['ribavirin', 6]], 'Vitamin B2 deficiency': [['riboflavin', 5]], 'Need for immunization against rubella alone': [['rubella vaccine', 3]], 'Seborrhoeic dermatitis': [['salicylic acid', 5], ['selenium sulfide', 2]], 'Ichthyoses': [['salicylic acid', 5]], 'Pityriasis versicolor': [['selenium sulfide', 2], ['sodium thiosulfate', 15]], 'Neonatal conjunctivitis or dacryocystitis': [['silver nitrate', 1], ['tetracycline', 1]], 'Burns': [['silver sulfadiazine', 1]], 'Polycystic ovary syndrome': [['simvastatin', 2]], 'Acidosis': [['sodium hydrogen carbonate', 4]], 'Hypertensive crisis': [['sodium nitroprusside', 5]], 'Respiratory distress syndrome of newborn': [['surfactant', 7]], 'Testicular dysfunction or testosterone-related disorders': [['testosterone', 2]], 'Need for immunization against tetanus alone': [['tetanus vaccine', 2]], 'Vitamin B1 deficiency': [['thiamine', 5]], 'Need for immunization against arthropod-borne viral encephalitis': [['tick-borne encephalitis vaccine', 5]], 'Malignant neoplasms of urinary tract': [['tislelizumab', 1]], 'Haemorrhage, not elsewhere classified': [['tranexamic acid', 1]], 'Fascioliasis': [['triclabendazole', 7]], 'Mycobacterial diseases': [['tuberculin, purified protein derivative', 5]], 'Need for immunization against typhoid-paratyphoid alone': [['typhoid vaccine', 1]], 'Xerosis cutis or asteatosis': [['urea', 5]], 'Cytomegaloviral retinitis': [['valganciclovir', 9]], 'Supraventricular tachyarrhythmia': [['verapamil', 8]], 'Invasive aspergillosis': [['voriconazole', 2]], 'Other specified diseases of arteries or arterioles': [['warfarin', 5]], 'Cerebral ischaemic stroke due to embolic occlusion': [['warfarin', 5]], 'Atrial fibrillation': [['warfarin', 5]], 'Unspecified appropriateness of dosing or administration without injury or harm': [['water for injection', 5]], 'Nasal congestion': [['xylometazoline', 5]], 'Mantle cell lymphoma': [['zanubrutinib', 8]], 'Malignant neoplasm metastasis in bone or bone marrow': [['zoledronic acid', 4]]}\n"
     ]
    }
   ],
   "source": [
    "import csv\n",
    "\n",
    "dict2 = {}\n",
    "\n",
    "# opening the CSV file\n",
    "with open('who.csv', mode='r') as file:\n",
    "    # reading the CSV file\n",
    "    csvFile2 = csv.DictReader(file)\n",
    "\n",
    "    # displaying the contents of the CSV file\n",
    "    for lines in csvFile2:\n",
    "        disease = lines['Indication']\n",
    "        quantity = lines['Formulations']\n",
    "        quantity = quantity.replace(\" \", \"\")\n",
    "        contents = lines['Medicine name']\n",
    "        contents = contents.replace(\" + \",\"/\")\n",
    "        contents = contents.replace(\"+ \",\"/\")\n",
    "        contents = contents.replace(\" +\",\"/\")\n",
    "        contents = contents.replace(\"+\",\"/\")\n",
    "        #print(content_array)\n",
    "        \n",
    "        for i in range(len(quantity)):\n",
    "            if (i<=len(quantity)-2):\n",
    "                if (quantity[i]=='m' and quantity[i+1]=='g'):\n",
    "                    i = i-1\n",
    "                    qua = 0\n",
    "                    factor = 1\n",
    "                    while(quantity[i].isdigit()):\n",
    "                        qua = qua+factor*int(quantity[i])\n",
    "                        i-=1\n",
    "\n",
    "            if (quantity[i]=='%'):\n",
    "                i = i-1\n",
    "                qua = 0\n",
    "                factor = 1\n",
    "                while(quantity[i].isdigit()):\n",
    "                    qua = qua+factor*int(quantity[i])\n",
    "                    factor = factor*10\n",
    "                    i-=1\n",
    "        \n",
    "        \n",
    "        \n",
    "        arr = []\n",
    "        arr.append(contents)\n",
    "        arr.append(qua)\n",
    "            \n",
    "        if disease not in dict2:\n",
    "            dict2[disease] = []\n",
    "            dict2[disease].append(arr)\n",
    "\n",
    "        else:\n",
    "            dict2[disease].append(arr)\n",
    "        \n",
    "print(dict2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 215,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified': 90583, 'Other specified malignant neoplasms of breast': 36410, 'Malignant neoplasms of prostate': 1184491, 'Primary open-angle glaucoma': 463629, 'Infectious diseases of external ear': 100841, 'Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs': 7440, 'Acute or subacute hepatic failure': 7440, 'Migraine': 387405, 'Acute myocardial infarction': 0, 'Cerebral ischaemic stroke': 0, 'Acute rheumatic fever without mention of heart involvement': 0, 'Mucocutaneous lymph node syndrome': 0, 'Juvenile idiopathic arthritis': 657193, 'Pain': 581373, 'Zoster': 0, 'Varicella': 0, 'Herpes simplex infections': 0, 'Herpes simplex keratitis': 0, 'Chronic obstructive pulmonary disease': 479864, 'Unspecified injury, poisoning or certain other consequences of external causes': 0, 'Axial spondyloarthritis': 97704, 'Crohn disease site': 173867, 'Rheumatoid arthritis': 97704, 'Other specified malignant neoplasms of bronchus or lung': 1495, 'Filariasis': 448, 'Echinococcosis': 448, 'Ascariasis': 7078, 'Enterobiasis': 568, 'Trichuriasis': 7078, 'Hookworm diseases': 7078, 'Cysticercosis': 448, 'Other specified echinococcosis': 568, 'Cysticercosis of central nervous system': 518, 'Denatured alcohol': 0, 'Muscle relaxants': 0, 'Acute myeloid leukaemia with recurrent genetic abnormalities': 6675, 'Gout': 374350, 'Tumour lysis syndrome': 504180, 'Amidotrizoate': 0, 'Neutropenia (high-risk)': 13275, 'Acute pyelonephritis (severe)': 0, 'Inflammatory and other diseases of prostate (severe)': 0, 'Sepsis without septic shock': 1070605, 'Other specified conjunctivitis': 90364, 'Infectious blepharitis': 12473, 'Multi-drug resistant Mycobacterium tuberculosis': 187672, 'Oedema': 6636109, 'Ascites': 802223, 'Cardiac arrhythmia': 2456664, 'Palliative care': 1027066, 'Depressive disorders': 2400, 'Essential hypertension': 6256451, 'Malaria due to Plasmodium falciparum': 0, 'Malaria': 0, 'Acute otitis media': 1070605, 'Acute pharyngitis': 1101401, 'Chronic obstructive pulmonary disease with acute exacerbation': 1070605, 'Periapical abscess without sinus': 1070605, 'Acute malnutrition in infants, children or adolescents (uncomplicated) [children]': 1070605, 'Acute malnutrition in infants, children or adolescents (complicated) [children]': 1070605, 'Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)': 1070605, 'Bacterial pneumonia (Community-acquired pneumonia - severe) [children]': 1070605, 'Acute sinusitis': 1070605, 'Bacterial meningitis': 1070605, 'Bacterial infection of unspecified site': 1270719, 'Infectious cystitis': 1298325, 'Bacterial cellulitis, erysipelas or lymphangitis': 0, 'Neutropenia (low-risk)': 765, 'Other specified pneumonia (Hospital-acquired pneumonia)': 0, 'Peritonitis (mild-moderate)': 596250, 'Peritoneal abscess (mild-moderate)': 596250, 'Bacterial infection of joint': 0, 'Osteomyelitis or osteitis': 0, 'Other specified prophylactic measures': 198495, 'Bacterial pneumonia (Community-acquired pneumonia - severe)': 91065, 'Blastomycosis': 0, 'Aspergillosis': 0, 'Cryptococcosis': 521460, 'Candidosis': 861635, 'Coccidioidomycosis': 0, 'Histoplasmosis': 570, 'Sporotrichosis': 570, 'Visceral leishmaniasis': 0, 'Peritonitis (severe)': 409915, 'Peritoneal abscess (severe)': 409915, 'Juvenile systemic arthritis': 8677, 'Malignant neoplasms of breast': 59097, 'Systemic or invasive candidosis': 0, 'Maternal care for red cell antibodies': 0, 'Rh incompatibility reaction': 0, 'Rabies': 0, 'Tetanus': 0, 'Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified': 0, 'Venous thromboembolism': 854943, 'Other specified atrial fibrillation': 854943, 'Nausea or vomiting': 435466, 'Malaria due to Plasmodium vivax': 0, 'Scurvy': 0, 'Lymphoid leukaemia, not elsewhere classified': 2250226, 'Unspecified malignant neoplasms of ill-defined or unspecified sites': 74969, 'Angina pectoris': 2626786, 'Mixed hyperlipidaemia': 1225631, 'Coronary atherosclerosis': 1225631, 'Exposure to or harmful effects of undetermined intent of pesticides': 17772, 'Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics': 17772, 'Cycloplegic drug': 17772, 'Anterior uveitis': 49020, 'Myeloid leukaemia': 65, 'Rheumatoid arthritis, serology unspecified': 89880, 'Psoriatic arthritis': 40545, 'Failure or rejection of transplanted organs or tissues': 65375, 'Relapsing-remitting multiple sclerosis': 49091, 'Chlamydia trachomatis': 801845, 'Paratyphoid fever': 802610, 'Typhoid fever': 802610, 'Gonococcal infection': 1604058, 'Trachoma': 1603749, 'Yaws': 801845, 'Cholera': 802610, 'Cholera [children]': 802610, 'Infectious gastroenteritis or colitis without specification of infectious agent': 802978, 'Other specified bacterial diseases': 25321, 'Barium sulfate with suspending agents': 0, 'Need for immunization against tuberculosis': 0, 'Asthma': 1545343, 'Chronic lymphocytic leukaemia or small lymphocytic lymphoma': 1150939, 'Follicular lymphoma': 1133240, 'Congenital syphilis [children]': 0, 'Syphilis': 0, 'Chagas disease': 0, 'Fungal infection of the skin': 0, 'Acne': 370, 'Pthiriasis': 0, 'Pediculosis corporis': 16865, 'Pediculosis capitis': 16865, 'Scabies': 23397, 'Pruritus due to skin disorder': 34037, 'Psoriasis of unspecified type': 105272, 'Dermatitis or eczema': 34037, 'Lichen planus': 34037, 'Age related macular degeneration': 371, 'Other specified melanoma of skin': 638, 'Parkinson disease': 393600, 'Constipation': 0, 'Heart failure': 10127705, 'Germ cell tumour of testis': 491, 'Hodgkin lymphoma': 1132955, 'Other specified malignant neoplasms of the ovary': 725, 'Kaposi sarcoma of unspecified primary site': 234, 'Plasma cell myeloma': 1322604, 'Allergic rhinitis': 371095, 'Anuria or oliguria': 1085121, 'Local anaesthetics': 77992, 'Opioid dependence': 39655, 'Nicotine dependence': 0, 'Hereditary angioedema': 300, 'Apnoea of newborn': 0, 'Pruritus': 0, 'Calcium deficiency': 55, 'Malignant neoplasm metastasis in large intestine': 35670, 'Burkitt lymphoma including Burkitt leukaemia': 2247591, 'Osteosarcoma of bone and articular cartilage of unspecified sites': 4531, 'Malignant neoplasms of rectum': 35590, 'Malignant neoplasms of colon': 35670, 'Malignant trophoblastic neoplasms of placenta': 4680, 'Hypermagnesaemia': 0, 'Tetany due to acute calcium deficiency': 0, 'Type 2 diabetes mellitus': 818725, 'Acute angle closure with pupillary block': 0, 'Ocular hypertension': 123595, 'Epilepsy or seizures': 203845, 'Bipolar or related disorders': 102992, 'Postpartum haemorrhage': 23468, 'Thyrotoxicosis': 23783, 'Other specified gliomas of brain': 3131, 'Other specified carcinomas of ovary': 660, 'Retinoblastoma': 491, 'Malignant neoplasms of nasopharynx': 36170, 'Malignant neoplasms of kidney, except renal pelvis': 1066, 'Malignant neoplasms of lip, oral cavity or pharynx': 426, 'Malignant neoplasms of cervix uteri': 660, 'Surgical site infection': 0, 'Carbapenem-resistant Pseudomonas aeruginosa': 0, 'Carbapenem resistant Enterobacterales': 0, 'Inflammatory and other diseases of prostate (mild to moderate)': 765, 'Acute pyelonephritis (mild to moderate)': 765, 'Endophthalmitis': 5124, 'Pseudomonas aeruginosa resistant to other antibiotic': 4424, 'Necrotising fasciitis': 198845, 'Allergic or hypersensitivity conditions of unspecified type': 1284027, 'Omphalitis of newborn': 0, 'Chlorhexidine': 0, 'Disinfectant, not elsewhere classified': 0, 'Malaria due to Plasmodium ovale': 0, 'Malaria due to Plasmodium malariae': 0, 'Phenol disinfectant, not elsewhere classified': 0, 'Schizophrenia or other primary psychotic disorders': 866454, 'Infectious keratitis': 74450, 'Need for immunization against cholera alone': 0, 'Gastro-oesophageal reflux disease': 2127694, 'Peptic ulcer, site unspecified': 2127694, 'Helicobacter pylori associated gastric ulcer': 30355, 'Leprosy': 14714, 'Female infertility without specification whether primary or secondary': 0, 'Obsessive-compulsive disorder': 0, 'Generalised myoclonic seizure': 1669535, 'Acute ischaemic heart disease': 0, 'Presence of coronary angioplasty implant or graft': 0, 'Vulvovaginal candidosis': 166360, 'Coagulation defects, purpura or other haemorrhagic or related conditions': 0, 'Haemophilia B': 0, 'Haemophilia A': 0, 'Cough': 1165, 'Diarrhoea': 3495, 'Vitamin D deficiency': 0, 'Carbapenem resistant Acinetobacter baumannii': 0, 'Other specified disorders of fluid, electrolyte or acid-base balance': 70695, 'Hypovolaemic shock': 0, 'Contact with health services for contraceptive management': 3775, 'Contact with health services for insertion of contraceptive device': 5285, 'Anaemias or other erythrocyte disorders': 0, 'Diffuse large B-cell lymphomas': 1133240, 'Ewing sarcoma of bone and articular cartilage of unspecified sites': 640, 'Rhabdomyosarcoma primary site': 575, 'Chronic hepatitis C': 2772, 'Anaemia due to chronic disease': 521, 'Chronic myeloid leukaemia, not elsewhere classified': 3270, 'Other specified sickle cell disorders or other haemoglobinopathies': 2300, 'Harmful effects of drugs, medicaments or biological substances, not elsewhere classified': 0, 'Methicillin resistant Staphylococcus aureus': 9176, 'Need for immunization against certain single viral diseases': 0, 'Von Willebrand disease': 0, 'Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy': 151712, 'Hypovolaemia': 0, 'Status epilepticus': 1136202, 'Anxiety': 110082, 'Persistent hyperinsulinaemic hypoglycaemia of infancy': 125, 'Lymphatic filariasis': 6510, 'Amoebiasis': 199025, 'Need for immunization against diphtheria alone': 0, 'Need for immunization against diphtheria-tetanus-pertussis, combined': 0, 'Need for immunization against combinations of infectious diseases': 0, 'Cardiogenic shock': 0, 'African trypanosomiasis': 0, 'Contact with or exposure to human immunodeficiency virus': 13651, 'Chronic hepatitis B': 19628, 'Cardiac complications of anaesthesia during labour or delivery': 0, 'Cardiac arrest': 13278, 'Anaphylaxis': 33774, 'Gonococcal infection of eye': 315, 'Chlamydial conjunctivitis': 315, 'Contact with health services for reasons associated with reproduction': 53460, 'Tuberculosis': 973, 'Other specified tuberculosis': 247, 'Anaesthetics and therapeutic gases': 0, 'Contact with health services for postcoital contraception': 3775, 'Absence seizures, typical': 1337, 'Chronic cancer pain': 122250, 'Iron deficiency anaemia': 0, 'Maternal care for other specified conditions predominantly related to pregnancy': 0, 'Acquired neutropaenia': 384, 'Adrenocortical insufficiency': 58696, 'Fluorescein': 0, 'Dental caries': 0, 'Plantar warts': 35510, 'Folate deficiency anaemia': 5790, 'Cephalocele': 5790, 'Anencephaly or similar anomalies': 5790, 'Spina bifida': 5790, 'Blood transfusion without reported diagnosis': 0, 'Neuropathic pain': 5099928, 'Neonatal meningitis': 12925, 'Hypoglycaemia in the context of diabetes': 458, 'Hypoglycaemia without associated diabetes': 0, 'Glutaral nonmedicinal': 0, 'Dermatophytosis': 0, 'Need for immunization against single bacterial diseases': 0, 'Unstable angina': 0, 'Need for immunization against viral hepatitis': 0, 'Gestational hypertension': 19999, 'Scleritis': 31248, 'Ulcerative colitis': 75403, 'Megaloblastic anaemia due to vitamin B12 deficiency': 0, 'Squamous cell carcinoma of oropharynx': 0, 'Systemic lupus erythematosus': 0, 'Cutaneous lupus erythematosus of unspecified type': 0, 'Patent arterial duct': 481565, 'B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1': 0, 'Gastrointestinal stromal tumour of unspecified gastrointestinal sites': 0, 'Antibiotic resistant Acinetobacter baumannii': 0, 'Need for immunization against influenza': 0, 'Type 1 diabetes mellitus': 817888, 'Care involving peritoneal dialysis': 0, 'Iodine deficiency': 0, 'Povidone iodine': 0, 'X-ray contrast media, iodinated': 0, 'Latent tuberculosis': 0, 'Bradycardia': 0, 'Chronic pulmonary aspergillosis': 2116, 'Chromoblastomycosis': 570, 'Talaromycosis': 570, 'Paracoccidioidomycosis': 570, 'Strongyloidiasis': 6510, 'Ancylostomiasis': 6510, 'Onchocerciasis': 6510, 'Hypothyroidism': 0, 'Ventricular tachyarrhythmia': 38996, 'Vancomycin resistant Staphylococcus aureus': 8826, 'Vancomycin resistant Enterococcus': 8826, 'Severe pre-eclampsia': 11150, 'Eclampsia': 11150, 'Cerebral oedema': 480, 'Need for immunization against measles alone': 0, 'Excessive menstruation with irregular cycle': 53460, 'Mucocutaneous leishmaniasis': 0, 'Cutaneous leishmaniasis': 0, 'Osteosarcoma of bone and articular cartilage of other specified sites': 0, 'Attention deficit hyperactivity disorder': 77, 'Acquired methaemoglobinaemia': 0, 'Trichomoniasis': 198495, 'Intestinal infections due to Clostridioides difficile': 198845, 'Sedative-hypnotic and anxiolytic drugs': 235, 'Induced abortion': 0, 'Spontaneous abortion, incomplete, without complication': 23250, 'Unspecified obstetric condition': 23250, 'Opioids or related analgesics\\xa0and agents affecting opioid receptors': 0, 'Need for immunization against mumps alone': 0, 'Superficial bacterial folliculitis': 123542, 'Impetigo': 123542, 'Shigella resistant to unspecified antibiotic': 0, 'Unintentional exposure to or harmful effects of opioids or related analgesics': 0, 'Myasthenia gravis': 0, 'Anticholinesterase reversible': 0, 'Hymenolepiasis': 84, 'Diphyllobothriasis': 84, 'Taeniasis due to Taenia saginata': 84, 'Taeniasis due to Taenia solium': 84, 'Pellagra': 0, 'Preterm labour without delivery': 41486, 'Melanoma of skin': 336, 'Primary immunodeficiencies': 0, 'Gastrointestinal bleeding': 2119524, 'Influenza due to identified seasonal influenza virus': 0, 'Schistosomiasis due to Schistosoma mansoni': 0, 'Respiratory failure as acute or chronic': 0, 'Enzyme intestinal': 0, 'Pneumocystosis': 0, 'Need for immunization against pertussis alone': 0, 'Carcinoma of breast, specialised type': 390, 'Haemorrhagic disorder due to other specified circulating anticoagulants': 0, 'Haemorrhagic or haematological disorders of fetus or newborn': 0, 'Anogenital warts': 0, 'Need for immunization against poliomyelitis': 0, 'Hypokalaemia': 8118900, 'Tropical phagedaenic ulcer': 0, 'Pemphigus': 0, 'Other specified pyogenic bacterial infection of skin and subcutaneous tissue': 0, 'Paragonimiasis': 84, 'Clonorchiasis': 84, 'Opisthorchiasis': 84, 'Schistosomiasis': 84, 'Other specified congenital anomaly of great arteries including arterial duct': 0, 'Other specified polyneuropathy': 0, 'Vitamin B6 deficiency': 0, 'Sideroblastic anaemia': 0, 'Toxoplasmosis': 791, 'Need for immunization against rabies': 0, 'Retinal venous occlusions': 0, 'Diabetic macular oedema': 0, 'Degenerative high myopia': 0, 'Acute malnutrition in infants, children or adolescents': 0, 'Vitamin A deficiency': 0, 'Viral haemorrhagic fever, not elsewhere classified': 138, 'Vitamin B2 deficiency': 0, 'Need for immunization against rubella alone': 0, 'Seborrhoeic dermatitis': 852, 'Ichthyoses': 0, 'Pityriasis versicolor': 852, 'Neonatal conjunctivitis or dacryocystitis': 59, 'Burns': 9591, 'Polycystic ovary syndrome': 586234, 'Acidosis': 0, 'Hypertensive crisis': 0, 'Respiratory distress syndrome of newborn': 0, 'Testicular dysfunction or testosterone-related disorders': 9028, 'Need for immunization against tetanus alone': 0, 'Vitamin B1 deficiency': 0, 'Need for immunization against arthropod-borne viral encephalitis': 0, 'Malignant neoplasms of urinary tract': 0, 'Haemorrhage, not elsewhere classified': 218, 'Fascioliasis': 0, 'Mycobacterial diseases': 0, 'Need for immunization against typhoid-paratyphoid alone': 0, 'Xerosis cutis or asteatosis': 0, 'Cytomegaloviral retinitis': 0, 'Supraventricular tachyarrhythmia': 0, 'Invasive aspergillosis': 1546, 'Other specified diseases of arteries or arterioles': 0, 'Cerebral ischaemic stroke due to embolic occlusion': 0, 'Atrial fibrillation': 0, 'Unspecified appropriateness of dosing or administration without injury or harm': 0, 'Nasal congestion': 0, 'Mantle cell lymphoma': 0, 'Malignant neoplasm metastasis in bone or bone marrow': 536}\n"
     ]
    }
   ],
   "source": [
    "sevierty = {}\n",
    "check = []\n",
    "\n",
    "for disease in dict2:\n",
    "    if disease not in sevierty:\n",
    "        severe_num = 0\n",
    "        #print(disease)\n",
    "        for content in dict2[disease]:\n",
    "            #print(content)\n",
    "            ############# content[1] is coefficient\n",
    "            if content[0] in dict1:\n",
    "                check.append(content[0])\n",
    "                #print(\"YESS\")\n",
    "                #print(content[0])\n",
    "                severe_num = severe_num + content[1]*dict1[content[0]]\n",
    "                #print(content[1]*dict1[content[0]])\n",
    "        sevierty[disease] = severe_num\n",
    "\n",
    "    else:\n",
    "        #print(disease)\n",
    "        for content in dict2[disease]:\n",
    "            #print(content)\n",
    "            ############# content[1] is coefficient\n",
    "            if content[0] in dict1:\n",
    "                #print(\"YESS\")\n",
    "                #print(content[0])\n",
    "                severe_num = severe_num + content[1]*dict1[content[0]]\n",
    "                #print(content[1]*dict1[content[0]])\n",
    "        sevierty[disease] = sevierty[disease] + severe_num\n",
    "\n",
    "#print(check)\n",
    "print(sevierty)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 216,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# importing the required module\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# x axis values\n",
    "x = [x for x in sevierty]\n",
    "# corresponding y axis values\n",
    "y = [sevierty[x] for x in sevierty]\n",
    "\n",
    "# plotting the points\n",
    "plt.plot(x, y)\n",
    "\n",
    "# naming the x axisevierty\n",
    "plt.xlabel('Disease')\n",
    "# naming the y axis\n",
    "plt.ylabel('Sevierty')\n",
    "\n",
    "# giving a title to my graph\n",
    "plt.title('Graph')\n",
    "\n",
    "# function to show the plot\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 217,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('Heart failure', 10127705), ('Hypokalaemia', 8118900), ('Oedema', 6636109), ('Essential hypertension', 6256451), ('Neuropathic pain', 5099928)]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 3000x1000 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "from operator import itemgetter\n",
    "\n",
    "sev_data = (sorted(sevierty.items(), key=itemgetter(1), reverse=True)[:5])\n",
    "print(sev_data)\n",
    "\n",
    "courses = [x[0] for x in sev_data]\n",
    "values = [x[1] for x in sev_data]\n",
    "\n",
    "fig = plt.figure(figsize=(30, 10))\n",
    "\n",
    "# creating the bar plot\n",
    "plt.bar(courses, values, color='maroon', width=0.4)\n",
    "\n",
    "plt.xlabel(\"Disease\")\n",
    "plt.ylabel(\"Occurrence\")\n",
    "plt.title(\"Top 5 diseases of the state: \" + state)\n",
    "plt.show()\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.0"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
